Under the patronage of

Committees

Honorary Presidents
C Black, S Jablonska, F Wollheim, T Medsger

Steering Committee
DE Furst, L Guillemin, T Krieg, M Kuwana, M Matucci-Cerinic, U Müller-Ladner, J Seibold, K Takehara, A Tyndall, and the following Chairpersons:

1. Chairpersons of the Abstract Committee:
   O Distler, P Sampaio Barros
2. Chairpersons of the Clinical Committee:
   Y Allanore, D Khanna
3. Chairpersons of the Basic Science Committee:
   J Distler, R. Lafyatis, J Varga
4. Chairperson of the Workshops:
   P Clements
5. Liaison officer with the Scleroderma Workshop:
   C Denton, R Lafyatis
6. Chairpersons of the Mentoring Programme:
   L Czirjak, M Mayes

Local Organising Committee
President of the Portuguese Society of Rheumatology:
Joao Eurico Cabral da Fonseca
Committee: Ana Cordeiro (coordinator), Paulo Coelho, Catarina Resende, Maria Joao Salvador

Scientific Committee

Fesca Board
Ann Tyrrell Kennedy, President
Beata Garay-Toth, Vice-President
Despo Charalambous-Demetriou, Treasurer
Alexandra Portales, Secretary
Annelise Roennow, Counselor
Kim Fligelstone, Counselor
Nadine Paciotti, Counselor
Joep Welling, Counselor
THURSDAY, FEBRUARY 18

13:00-16:30  Pre-meeting Workshops
See information at page 11

16:45-17:45  Satellite Symposia
See information at page 14

18:00-18:30  Opening Ceremony  AUDITORIUM I
Welcome addresses and opening remarks

18:30-20:10  Opening Lectures  AUDITORIUM I
Chairpersons: T Krieg (D), D Furst (USA)

18:30  What is new in basic research
C Denton (UK)

18:55  On the cutting edge of clinical investigations
T Medsger (USA)

19:20  Results and lessons from the main clinical trials in the last 2 years
D Khanna (USA)

19:50  Where do we stand with the early recognition of systemic sclerosis
M Matucci-Cerinic (I)

20:10  Welcome Cocktail
FRIDAY, FEBRUARY 19

08:00-09:10 Session 1 AUDITORIUM I
PULMONARY INVOLVEMENT
Chairpersons: A Wells (UK), P Clements (USA)

08:00 Mycophenolate versus oral cyclophosphamide in scleroderma-related interstitial lung disease: results of scleroderma lung study II
D Tashkin (USA)

08:25 ASSOCIATION BETWEEN SKIN GENE EXPRESSION AND CLINICAL PHENOTYPE IN SYSTEMIC SCLEROSIS
M Hinchcliff, et al (USA)

08:40 INCIDENCES AND PREDICTORS OF ORGAN MANIFESTATIONS IN THE EARLY COURSE OF SYSTEMIC SCLEROSIS: A LONGITUDINAL EUSTAR STUDY
V Jaeger, et al (CH)

08:55 ANTIBODIES AGAINST CHEMOKINE RECEPTORS CXCR3 AND CXCR4 AS MARKER FOR LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS
G Riemekasten, et al (D)

09:15-10:40 Session 2 AUDITORIUM I
ULCERS
Chairpersons: A Herrick (UK), F Wigley (USA)

09:15 Biology of Raynaud’s phenomenon: therapeutic implications
N Flavahan (USA)

09:40 VASCULAR HYPOTHESIS REVISITED: ROLE OF STIMULATING ANTIBODIES AGAINST ANGIOTENSIN AND ENDOTHELIN RECEPTORS IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS
G Riemekasten, et al (D)

09:55 SENSITIVITY TO CHANGE OF NAILFOLD VIDEOCAPILLAROSCOPY AND RELATIONSHIP WITH DISEASE PROGRESSION
J Avouac, et al (F)

10:10 DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: PREDICTOR FACTORS
I Silva, et al (P)

10:25 PREVENTION OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: REAL LIFE DATA FROM THE DESSCIPHER OBSERVATIONAL STUDY OF THE EUSTAR GROUP
J Blagojevic, et al (UK)

10:40-11:00 Coffee break

11:00 Lecture 1 AUDITORIUM I
Chairpersons: E Hachulla (F), M Vonk (NL)
Pulmonary arterial hypertension: the challenge of screening for PAH in systemic sclerosis
N Galie (I)

11:25 Oral presentation AUDITORIUM I
MACITENTAN RESPONSIVENESS SUPPORTS THE VALIDITY OF A MURINE MODEL OF PULMONARY HYPERTENSION IN SCLERODERMA ASSOCIATED WITH ALTERED TGFbeta/BMPRII SIGNALLING
E Derret-Smith, et al (UK)

11:40 Lecture 2 AUDITORIUM I
Chairpersons: P Carreira (E), C Ferri (I)
Is there a role for Extracorporeal Photopheresis (ECP) in Systemic Sclerosis?
R Knobler (A)
Sponsored by Therakos
(now a part of Mallinckrodt)

12:15-13:45 Satellite Symposia
See information at page 14
13:45-14:45  Poster session & lunch break

14:45-15:25  Satellite Symposia
See information at page 14

15:30-16:55  Parallel Session 3  AUDITORIUM I
COMMON CLINICAL SITUATIONS WITH POOR EVIDENCE BASED DATA: HOW TO MANAGE?
Chairpersons: T Frech (USA), F van den Hoogen (NL)

15:30  Pregnancy & sexual problems
V Steen (USA)

15:30-16:55  Parallel Session 4  AUDITORIUM III
ADVANCES IN EPIGENETICS AND GENETICS
Chairpersons: J Distler (D), B Lafyatis (USA)

15:30  Epigenetic control of fibrogenesis and transgenerational epigenetic adaption of the wound healing response
D Mann (UK)

15:55  INHIBITION OF PHOSPHODIESTERASE 4 (PDE4) REDUCES DERMAL FIBROSIS BY INTERFERING WITH THE RELEASE OF PRO-FIBROTIC CYTOKINES FROM M2-MACROPHAGES
C Maier, et al (D)

16:10  EPITHELIAL FLI1 DELETION INDUCES FIBROSIS AND AUTOIMMUNITY WITH DOWNREGULATION OF AIRE – POSSIBLE ROLES IN SYSTEMIC SCLEROSIS PATHOGENESIS
Y Asano, et al (JPN)

16:25  ENDOTHELIAL-TO-MESENCHYMAL TRANSITION (ENDOMT) AS A KEY PROFIBROTIC SWITCH IN SYSTEMIC SCLEROSIS
M Manetti, et al (I)

16:40  WNT/PCP-SIGNALING AS A ß-CATENIN INDEPENDENT PATHWAY TO PROMOTE FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS
C Chen, et al (D)

16:55-17:15  Coffee break

17:15-19:10  Parallel Session 5  AUDITORIUM I
CARDIAC
Chairpersons: N Damjanov (SR), S Assassi (USA)

17:15  Cardiac involvement in systemic sclerosis. What should be known by the practitioners
A L Caforio (I)

17:40  INFLAMMATORY CELLS AND STROMAL SUB-POPULATIONS INVOLVEMENT IN THE MYOCARDIAL FIBROGENESIS IN SYSTEMIC SCLEROSIS
M Stellato, et al (CH)
17:55 N-TERMINAL PRO BRAIN NATRIURETIC PEPTIDE IS A STRONG PREDICTOR OF MORTALITY IN SYSTEMIC SCLEROSIS
J Avouac, et al (F)

18:10 CARDIAC BIOMarkers IN PRIMARY HEART INVOLVEMENT IN SYSTEMIC SCLEROSIS: NT-PROBNP AND TROPONIN T AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS
S Bosello, et al (I)

18:25 PROGNOSTIC ROLE OF VENTRICULAR ECTOPIC BEATS IN SYSTEMIC SCLEROSIS
S Bosello, et al (I)

18:40 EARLY DETECTION OF CARDIAC INVOLVEMENT BY MAGNETIC RESONANCE: CLINICAL CORRELATIONS IN SYSTEMIC SCLEROSIS
L Gargani, et al (I)

18:55 IMAGING PATTERNS OF STRESS PERFUSION-FIBROSIS IN SYSTEMIC SCLEROSIS USING CARDIOVASCULAR MAGNETIC RESONANCE
S Mavrogeni, et al (GR)

17:55 MULTI-ORGAN SYSTEMS BIOLOGY ANALYSIS OF SYSTEMIC SCLEROSIS REVEALS A MACROPHAGE SIGNATURE ASSOCIATED WITH DISEASE SEVERITY IN MULTIPLE END-TARGET TISSUES
M Whitfield, et al (USA)

18:10 INNATE LYMPHoid CELLS – NEW PLAYERS IN SYSTEMIC SCLEROSIS CORRELATE WITH EXTENT OF SKIN AND LUNG FIBROSIS
T Wolfahrt, et al (D)

18:25 TIE2 AS A NOVEL FACTOR OF PERIPHERAL MICROANGIOPATHY IN SYSTEMIC SCLEROSIS
B Maurer, et al (CH)

18:40 THE ROLE OF IL-17 CYTOKINE FAMILY MEMBERS IN SCLERODERMA SKIN
C Chizzolini, et al (CH)

18:55 ESTROGENS INHIBIT THE PROFIBROTIC EFFECTS OF TGF-BETA AND PROTECT FROM THE DEVELOPMENT OF EXPERIMENTAL DERMAL FIBROSIS
J Avouac, et al (F)
SATURDAY, FEBRUARY 20

08:00-09:00 Session 7
MEET THE PROFESSOR SESSIONS

Autoantibodies: Practical Implications for Diagnosis & Prognosis
T Medsger (USA) & O Distler (CH)

PAH versus PH: Why the difference matters
V Steen (USA) & C Denton (UK)

SSc ILD: Stable vs Progressive Disease: To treat or not to treat
G Riemekasten (D) & D Tashkin (USA)

Cardiac: Practical Guide to Screening and Evaluation
Y Allanore (F) & U Müller-Ladner (D)

GI: GERD/GAVE and Small Bowel Nutrition
D Khanna (USA) & J Clarke (USA)

MSK: Evaluation of the “puffy hand” arthritis vs tenosynovitis
P Clements (USA) & M Mayes (USA)

Digital ulcers: evaluation, treatment and pain management
M Matucci-Cerinic (I) & F Wigley (USA)

Progressive skin disease - approach to evaluation and management
D Furst (USA) & L Czirjak (H)

09:05 Lecture 3
Chairpersons: B Kahaleh (USA), A Gabrielli (I)
Anti-RNA polymerase III antibody: from its discovery to utility in clinical practice and basic research
M Kuwana (JPN)

09:30 Oral Presentation
INCREASED FREQUENCY OF MALIGNANCIES, AND IN PARTICULAR BREAST CANCER, SYNCHRONOUS TO THE ONSET OF SYSTEMIC SCLEROSIS IN ANTI-RNA POLYMERASE III ANTIBODIES POSITIVE PATIENTS: A EUSTAR MULTICENTRE STUDY
M Lazzaroni, et al (I)

09:40 Lecture 4
Chairpersons: U Müller-Ladner (D), L Hummers (USA)
Upper and lower gastrointestinal/nutrition
J Clarke (USA)

10:05 Oral Presentation
IMPAIRED MICRONUTRIENT STATUS IN PATIENTS WITH SYSTEMIC SCLEROSIS
R Dobrota, et al (CH)

10:20-10:40 Coffee break

10:40-12:00 Session 8
ROUND TABLE SSC REGISTRIES IN THE WORLD
Chairpersons: M Mayes (USA), T Krieg (D)

10:40 Y Allanore introducing EUSTAR and PHENOTYPES DETERMINED BY CLUSTER ANALYSIS AND THEIR SURVIVAL IN THE PROSPECTIVE EUSTAR COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
V Sobanski, et al (F)
10:55 T Krieg introduces DSNW and
LOW FREQUENCY OF RENAL CRISIS IN MORE THAN 3100
PATIENTS OF THE GERMAN NETWORK FOR SYSTEMIC
SCLERODERMA (DNSS)
N Hunzelmann, et al (D)

11:10 M Baron introduces Canadian network and
GUIDELINES FOR THE RATIONAL USE OF FOLLOW-
UP CARDIAC ECHOCARDIOGRAPHY TO SCREEN FOR
PULMONARY ARTERIAL HYPERTENSION (PAH) IN SYSTEMIC
SCLEROSIS (SSC)
M Baron, et al (CND)

11:25 S Proudman Introduces the Australian registry and
DETERMINANTS OF UNEMPLOYMENT AMONGST
AUSTRALIAN SCLERODERMA PATIENTS: RESULTS FROM A
LARGE MULTICENTRE COHORT STUDY
K Morrisroe, et al (AUS)

11:40-12:00 Discussion

12:00 Lecture 5
Chairpersons: L Czirjak (H),
S Proudman (A)
LcSSc the unfairly neglected subset
of systemic sclerosis?
Y Allanore (F)

12:25 Oral Presentation
Chairpersons: L Czirjak (H),
S Proudman (A)
SURVIVAL AND ORGAN INVOLVEMENT IN PATIENTS
WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS AND
ANTI-TOPOISOMERASE ANTIBODIES: MORE LIKE LIMITED
CUTANEOUS OR MORE LIKE DIFFUSE CUTANEOUS
SYSTEMIC SCLEROSIS?
P Kranenburg, et al (NL)

12:40-13:30 Poster session & lunch break

13:30-14:45 Parallel Session 9
EXPERIMENTAL MODELS
OF SCLERODERMA
Chairperson: P Coelho (P),
F del Galdo (UK)

13:30 UPAR-DEFICIENT MICE: A NOVEL EXPERIMENTAL MODEL
OF DELAYED CUTANEOUS WOUND HEALING TO EXPLORE
SYSTEMIC SCLEROSIS–RELATED DIGITAL ULCERS
S Kotzki, et al (F)

13:40 GLI2 AS A TARGET FOR ANTIFIBROTIC THERAPIES IN
PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS
J Distler, et al (D)

13:50 SMALL PEPTIDES DERIVED FROM MET RECEPTOR
TYROSINE KINASE AS NEW THERAPEUTIC APPROACH FOR
THE TREATMENT OF SCLERODERMA
G Bogatkevich, et al (USA)

14:00 CM-101, A NOVEL MONOCLONAL ANTIBODY BLOCKING
CCL24 AMELIORATES EXPERIMENTAL SYSTEMIC SCLEROSIS
(SSC) AND IDIOPATHIC PULMONARY FIBROSIS (IPF) and
A NOVEL ANTIBODY BLOCKING CCL24/CCR3 REDUCES
CHEMOKINESIS OF IMMUNE CELLS AND THE TRANSITION
OF FIBROBLASTS TO MYOFIBROBLASTS IN SYSTEMIC
SCLEROSIS (SSC)
A Mor, et al (ISR)

14:15 EFFECTS OF NINTEDANIB ON FIBROTIC AND VASCULAR
MANIFESTATIONS IN PRECLINICAL MODELS OF SYSTEMIC
SCLEROSIS
J Distler, et al (D)

14:25 M2-SHIFTED MICE RECAPITULATE DERMAL AND
PULMONARY REMODELING
H Yassoka, et al (JPN)
14:35 NOX4 IS A CRUCIAL MEDIATOR OF TGF-BETA1-INDUCED FIBROBLAST ACTIVATION OF DERMAL FIBROBLASTS – NOVEL FINDINGS FROM IN VITRO AND IN VIVO SCLERODERMA RESEARCH
M Bohm, et al (D)

13:30-14:40 Parallel Session 10 AUDITORIUM I
OUTCOME MEASURES
Chairperson: E Kucharz (PL), S Johnson (CND)

13:30 PREDICTION OF IMPROVEMENT IN SKIN FIBROSIS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS - A EUSTAR ANALYSIS
R Dobrota, et al (CH)

13:40 DEVELOPMENT OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS USING CONSENSUS AND DATA DRIVEN METHODS
N Ferdowsi, et al (AUS)

13:50 EUSTAR TASK FORCE FOR THE DEVELOPMENT OF A REVISED ACTIVITY CRITERIA FOR SYSTEMIC SCLEROSIS
M Iudici, et al (I)

14:00 COMPLEMENTARY VALUE OF ELF TEST AND NT-PROBNP IN REFLECTING FIBROSIS AND VASCULOPATHY IN SYSTEMIC SCLEROSIS
G Abignano, et al (UK)

14:10 THE SCLERODERMA FIBROTIC SCORE: A USEFUL SERUM TEST IN THE DIAGNOSIS OF EARLY SCLERODERMA
J Blagojevic, et al (UK)

14:20 VERY EARLY AND EARLY SYSTEMIC SCLEROSIS PATIENTS IN THE SPANISH SCLERODERMA REGISTRY (RESCLE) COHORT
L Trapiella, et al (E)

14:30 FROM VEDOSS TO ESTABLISHED SYSTEMIC SCLEROSIS DIAGNOSIS ACCORDING TO THE NEW ACR/EULAR 2013 CLASSIFICATION CRITERIA: A CAPILLAROSCOPIC SURVEY
M Vasile, et al (I)

14:45-16:10 Session 11 AUDITORIUM I
EMERGING THERAPIES
Chairpersons: K Takehara (JPN), J Seibold (USA)

14:45 Emerging therapies
O Distler (CH)

15:10 EFFICACY OF MYCOPHENOLATE MOFETIL (MMF) VERSUS ORAL CYCLOPHOSPHAMIDE (CYC) ON SKIN THICKNESS IN THE SCLERODERMA LUNG STUDY II
D Khanna, et al (USA)

15:25 BASELINE CHARACTERISTICS AND TREATMENT CHOICES IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (ESOS COHORT)
A Herrick, et al (UK)

15:40 INHIBITION OF MYELOID-ASSOCIATED GENE EXPRESSION IN SKIN BIOPSY SAMPLES OF SYSTEMIC SCLEROSIS PATIENTS TREATED WITH TOCILIZUMAB
R Lafyatis, et al (USA)

15:55 TREATING SCLERODERMA OF THE FACE AND HANDS WITH FAT AND STROMAL VASCULAR FRACTION
G Magalon, et al (F)

16:15-16:55 Closing Lectures AUDITORIUM I
Chairpersons: A Balbir-Gurmann (ISR), JE Cabral da Fonseca (P)

16:15 New EULAR recommendations for the treatment of systemic sclerosis
O Kowal-Bielecka (PL)
16:35 Review of the most relevant works presented at the congress
  D Furst (USA)

16:55-17:00 Closure of the congress
Workshops will be held on Thursday, February 18. 90 minutes workshops will be repeated twice, 180 minutes workshops all at once.

Reservation is requested. Left places can be booked at the “New Registration” desk in the registration area.

Coordinator: Phil Clements (USA)

**90 minutes workshops**
The following 90 minutes workshops will be held twice:

- From 13:00 to 14:30 first slot and
- From 15:00 to 16:30 second slot

**How to take skin biopsies**  
Convenors: O Distler (CH), C Beyer (D)  
ROOM 1.02

**Skin scoring**  
Convenors: P Clements (USA), L Czirjak (H), D Furst (USA), M Mayes (USA)  
ROOM 1.07

13:00-13:15 / 15:00-15:15 Why do the skin score?  
13:15-13:30 / 15:15-15:30 How to do the skin score  
13:30-14:30 / 15:30-16:30 Skin scoring - hands on skin scoring of 3 patients

**Risk Assessment for ILD in patients with Systemic Sclerosis**  
Convenor: R Saggar (USA)  
ROOM 1.05

**The local management of digital ulcers**  
Convenor: M Matucci-Cerinic (I)  
ROOM 1.06

13:00/15:00 DU in systemic sclerosis: from clinical evidence to treatment  
M Matucci-Cerinic (I)

13:15/15:15 The management of DU infections in systemic sclerosis  
D Giuggioli (I)
13:30/15:30 Hands on work on 3 patients  
F Braschi (I), M Niederer-Spinazzè (CH)

180 minutes workshops  
The following 180 minutes workshops will be held from 13:00 to 16:30 – one slot only

Capillaroscopy 2016: UP TO DATE  
ROOM 3A  
Convenor: M Cutolo (I)

13:00 Capillaroscopy 2016: a true diagnostic tool  
M Cutolo (I)

13:10 Capillaroscopy only hot in Raynauds and systemic sclerosis or also important throughout other connective tissue diseases?  
A L Herrick (UK)

13:40 How to distinguish the pathological capillaroscopic patterns from a normal pattern and role in prediction of clinical complications in systemic sclerosis  
V Smith (B)

14:10 Reliability of qualitative and quantitative capillaroscopic assessment: links with peripheral blood flow and skin fibrosis  
A Sulli (I)

14:40 Coffee break

15:10 What’s new: Capillaroscopy and other microcirculatory tools in assessment of therapies in Rheumatic diseases: where are we and where do we head at?  
M Cutolo (I)

15:40 Q&A

15:50 Capillaroscopy on living cases  
All tutors

Localized scleroderma Diagnosis, Classification and Therapy  
ROOM 1.03  
Convenors: R Knobler (A), T Krieg (D), K Takehara (JPN)

13:00 Introduction  
T Krieg (D)

13:05 Pseudosclerodermatous diseases. How to make a diagnosis  
F Rongioletti (I)

13:25 Classification of localized scleroderma and the European approach  
P Moinzadeh (D)

13:35 Classification of localized scleroderma the US experience  
H Jacobe (USA)

13:45 Lessons from the Japanese registry  
Y Asano (JPN)

13:55 Discussion

14:05 Selected case presentations diagnostic challenges  
A Kreuter (D), L Rudnicka (PL)

14:30 Coffee Break

15:00 Topical and UV-associated therapy of localized scleroderma  
R Knobler (A)
15:20 Systemic therapies
   J Seneschal (F)

15:40 Selected case presentations
difficult treatment decisions
   I Foeldvari (D), P Moinzadeh (D)

16:05 New therapeutic developments based on
pathophysiological concepts
   N Hunzelmann (D)

16:25 Summary
   K Takehara (JPN)

Quantitative scoring of HRCT
Convenor: J Goldin (USA)
Outline:
1 Review of ct findings in SLD
2 Visual and quantitative measures and role in prediction
   and outcome
3 Visual scoring techniques
   1 quick disease extent (wells)
   2 semi quantitative by lobe and component
4 Training cases
5 Test cases
6 Review of test cases

Ultrasound in systemic sclerosis;
Improving its management in clinical practice
Convenor: E Naredo (E)  ROOM 1.08

13:00 Welcome
   Clinical case
   E Naredo (E)

13:05 Anatomic basis for musculoskeletal
   involvement in systemic sclerosis
   I Møller (E)

13:30 Joint inflammation (i.e. synovitis and
   tenosynovitis) in systemic sclerosis;
   Do we need ultrasound?
   A Iagnocco (I)

13:55 How can ultrasound help in lung
   involvement?
   L Gargani (I)

14:30 Coffee break

15:00 Workshop on joints and lung
   in systemic sclerosis
**BAYER SATELLITE SYMPOSIUM**

**Thursday, February 18**  
16:45-17:45

**SGC STIMULATION – AN INNOVATIVE TREATMENT OPTION IN MANAGEMENT OF PAH-CTD**

Chairperson: G Riemekasten (D)

Welcome and introduction  
G Riemekasten (D)

16:50 sGC stimulation:  
Understanding the mode of action  
J Distler (D)

17:00 Screening for and diagnosing PAH in systemic sclerosis patients  
D Khanna (USA)

17:10 sGC stimulation in PAH-CTD patients:  
Results from the PATENT studies  
C Denton (UK)

17:20 Updated EULAR guidelines for the treatment of systemic sclerosis: What does it mean for PAH-CTD?  
O Kowal-Bielecka (PL)

17:30 Discussion

---

**ACTELION SATELLITE SYMPOSIUM**

**Friday, February 19**  
12:15-13:45

**IMPROVING OUTCOME IN PULMONARY ARTERIAL HYPERTENSION**

Chairpersons: O Distler (CH), M Matucci-Cerinic (I)

12:15 Introduction  
M Matucci-Cerinic (I)

12:20 Improving screening in PAH – Personal experience with the DETECT algorithm  
D Khanna (USA)

12:40 Improving trial design in PAH – Results from recent trials  
C Denton (UK)

13:00 Improving PAH management – Addressing the three pathways  
M Humbert (F)

13:20 Improving quality of life – Are we addressing patients’ needs?  
U Müller-Ladner (D)

13:40 Panel discussion
NEW AMBITIONS IN PAH-SSC

New EU Guidelines and their relevance to SSC-PAH
C Denton (UK)

The AMBITION trial: The PAH-SSc results
J Langley (UK)
THURSDAY, FEBRUARY 18

15:00-17:00 Round-table Networking Meeting for Leaders of Patient Associations
Theme: “Patient Participation”

18:00-21:30 Opening Lectures and Welcome Reception for clinicians and patients

FRIDAY, FEBRUARY 19

09:00-09:10 FESCA welcome: A Kennedy (IRL)  ROOM 3B

09:10-09:30 What Do we Know about Scleroderma Now? Prof. C Denton (UK)  ROOM 3C

09:30-10:30 What will Help my Digestive Problems? Chairpersons: A Kennedy (IRL), C Denton (UK)  ROOM 3C

SIMULTANEOUS TRANSLATION OFFERED IN room 3C
PATIENT POSTER DISPLAY AREA
FILM BY CHRISTY McCAFFREY (twice shown in room 3A)

09:30-10:00 Parallel Session Chairperson: J Welling (NL)  ROOM 3B

New systemic sclerosis Classification and Management Recommendations Prof. F Van den Hoogen (NL)
10:00-10:30 **Parallel Session**
**ROOM 3B**
Chairperson: K Fligelstone (UK)

ScleroID – a New Patient-Reported Outcome Measure
Dr. R Dobrota (CH), Dr. M Becker (D)

10:30 -11:00 **Coffee Break**

11:00-12:00 **What will Help me Breathe Easily?**
**Is my Heart Involved?**
**ROOM 3C**
Chairpersons: A Portales (E), Dr. A Herrick (UK)

Understanding lung problems
Prof. O Distler (CH)

PAH and the Heart
Dr. A Cordeiro (P), Dr. M J Loureiro (P)

Struggles with Breathing
A Roennow (DK)

11:00-12:00 **Parallel Session**
**ROOM 3B**
EU projects with FESCA as partner
Chairperson: B Garay-Toth (H)

DeSScipher
Prof. U Müller-Ladner (D)

The Value of Patient Participation
Prof. Y Allanore (F)

12:00-13:00 **Parallel Session**
**ROOM 3B**
For Men with systemic sclerosis and Husbands of those with systemic sclerosis
Chairperson: J Welling (NL)

What will Help Men cope with systemic sclerosis?
Prof. S Santos (P), J Welling (NL)

Panel Discussion in English and Portuguese

13:00-14:00 **Lunch**

14:00-14:40 **What will Cure the Pain of Digital Ulcers & Calcinosis?**
**ROOM 3C**
Chairpersons: D Charalambous (CY), E Mateus (P)

Our Recommendations for Treatment of Ulcers
Prof. M Matucci-Cerinic (I)

How we Care for Ulcers in a Portuguese Clinic
Prof. J Delgado Alves (P)

Pain: The Greatest Struggle for Many Patients
Y Courcoux (F)
14:40-15:15 How do I Cope with my Facial Changes?
ROOM 3C
Chairpersons: B Garay-Toth (H), Prof. P Carreira (E)
Changing Faces and Self-Esteem
Prof. A Tyndall (CH)
Readjusting my Life
M Sauvé (CND)

My Story
S Sandulescu (ROM)

14:00-15:00 Parallel Session - Panel Discussion
Juvenile Scleroderma
Chairpersons: K Fligelstone (UK)
Moving On from systemic sclerosis
Dr. I Foeldvari (D), G Verzi (I), A. Alferes Pereira (P)

15:15-16:30 How Can I Manage Systemic Sclerosis Myself?
ROOM 3C
Chairpersons: N Paciotti (CH), Dr. M J Salvador (P)
Coping with the Everyday Challenges of Scleroderma
Dr. L Kwakkenbos (NL)
Do Support Groups Help?
V Delisle (CAN)
Painful Symptoms that Cannot be Measured
Dr. J Lee (CND)

Mind & Body Strength
Dr. L A Saketkoo (USA)

15:00-15:30 Parallel Session
ROOM 3B
Chairpersons: H Gaspar (P), A Portales (E)
Caring for your Teeth in systemic sclerosis
Dr. A Pequeno (in Portuguese)

15:30-16:30 Parallel Session
ROOM 3B
Scleroquizz Game
Nurse A Noullez (F), Nurse G Wojtasik (F)
(in English and French)

09:00-15:00 Parallel Session
ROOM 3A
Interactive Workshops. Exercises to Improve Breathing and Facial Flexibility
Therapists: J Brozd PT (CR), V Mišura PT (CR) and S Roskar (CR)

09:30-10.10 Breathing Exercises
10:15-10:45 Face Exercises
11:00-11:45 Face Exercises
12:00-13:00 Breathing Exercises
14:00-15:00 “Ask a Physiotherapist” – demonstration of exercises in response to questions.
SATURDAY, FEBRUARY 20

09:00-10:00 Meet the Professor: Answers to your questions in your own language in English - (translation into Portuguese, French, Spanish)
Chairperson: A Portales (E) Speakers: Prof. M Mayes (USA) & Prof. P Carreira (E)

in German
Chairperson: G Niehaus (D)
Speaker: Prof. U Müller-Ladner (D)

in Italian
Chairperson: G Tassini (I)
Speaker: Prof. M Matucci-Cerinic (I)

10:00-11:00 What is Research doing for Me? What New Therapies can I try?
Chairperson: J Welling (NL), Prof. A Tyndall (CH)

The Hope of Systemic Drugs
Prof. C Denton (UK)

Considering Stem-Cell Transplants
Prof. J Van Laar (NL)

My Lung Transplant
A Martin (CH)

My Stem-Cell Transplant
R Kanters (NL)

11:00-11:30 Coffee Break

11:30-12:00 After 10 years with systemic sclerosis, What Can I Expect?
Chairpersons: A Roennow (DK), Dr. P Coelho (P)

Predicting the Future with systemic sclerosis
Dr. J Lee (CND)

A Long Life With Systemic Sclerosis
K Fligelstone (UK)

12:00-13:00 Coping: How can my family and I manage systemic sclerosis better?
Chairpersons: A Kennedy (IRL), Dr. C Resende (P)

Dealing with Chronic Fatigue
Dr. J Poole (USA)

Breathing Exercises
Dr. J Poole (USA)

How to share systemic sclerosis with a loved one
H and E Lever (S)

Finding your way as a single mother
M Gaafar (CH)

A Meditation for stress relief
Dr. L A Saketkoo (USA)

10:30-11:30 Parallel Session
Wax Bath demonstrations
Dr. W Gregory PT (UK)

11:30-12:30 Parallel Session
Hand exercises
Dr. W Gregory PT (UK)
10:00-11:00 and 11:00-12:00
Parallel Sessions ROOM 3A
Screening of film “Beneath the Surface”
Christy McCaffrey (USA)

12:00-12:30 Parallel Session ROOM 3A
Chairperson: H Gaspar (P)
Nutrition in systemic scleriosis
A Cardoso (P) (in Portuguese)

13:00 Closure of Congress

13:30-15:30 Fesca Meeting of all Representatives
ROOM 3B
P.001 CAVEOLIN 1 GENE VARIANTS MAY EFFECT DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE
S. Yavuz, E. Lopez Isac, A.M. Onat, N. Yilmaz, L. Kilic, A. Akdogan, J. Martin

P.002 ALTERATIONS IN MIRNA CONTENT OF EXOSOMES ISOLATED FROM SERUM OF SYSTEMIC SCLEROSIS PATIENTS: A POTENTIAL MECHANISM FOR THE INITIATION AND PROGRESSION OF A PROFIBROTIC PHENOTYPE
P. Wermuth, S. Piera-Velazquez, S. Jimenez

P.003 DETECTION OF POTENTIAL SUSCEPTIBILITY FACTORS IN PATIENTS WITH SYSTEMIC SCLEROSIS IN POPULATION OF SERBIA
M. Vreca, V. Spasovski, M. Andjelkovic, M. Stojiljkovic, N. Tosic, A. Zekovic, N. Damjanov, S. Pavlovic

P.004 IDENTIFICATION OF NOVEL DRIVERS OF FIBROSIS IN SSC
J. Verneau, D. Abraham, T. Johnson, J. Norman, M. Ponticos

P.005 EXTRACELLULAR HEAT SHOCK PROTEIN 90 IS ASSOCIATED WITH DISEASE ACTIVITY, LUNG INVOLVEMENT AND SKIN FIBROSIS IN SYSTEMIC SCLEROSIS

P.006 INTERLEUKIN-35 IS OVEREXPRESSED IN SYSTEMIC SCLEROSIS AND ITS ELEVATED SERUM LEVELS ARE ASSOCIATED WITH EARLY DISEASE

P.007 ASSOCIATION STUDY OF A GLUTAMATE CYSTEIN LIGASE GENE POLYMORPHISM WITH SUSCEPTIBILITY TO SYSTEMIC SCLEROSIS
A. Tochimoto, Y. Kawaguchi, M. Kawamoto, K. Takagi, T. Higuchi, Y. Ichimura, H. Yamanaka

P.008 EXPOSURE TO QUARTZ DUST AND THE RISK OF DEVELOPMENT OF CONNECTIVE TISSUE DISEASES

P.009 ANTI-VINCULIN ANTIBODIES: POTENTIAL VASCULAR MARKERS IN SYSTEMIC SCLEROSIS PATIENTS

P.010 ENDOTHELIN-1 INDUCES HUMAN MONOCYTE POLARIZATION INTO ALTERNATIVELY ACTIVATED MACROPHAGES
S. Soldano, P. Montagna, A.C. Trombetta, R. Brizzolara, A. Sulli, C. Pizzorni, S. Paolino, M. Cutole

P.011 A RARE COEXISTENCE OF ANTI-CENTROMERE ANTIBODIES WITH ANTI-RNA POLYMERASE III & ANTI-TOPOISOMERASE-I ANTIBODIES
K. Solanki, A. Schollum

P.012 IMMUNOLOGICAL REVIEWS DURING SYSTEMIC SCLERODERMA
D. Si Ahmed, M. Bouali - Benhalima, F. Haddoum, L. Boudjella, F. Bouali

P.013 NOTCH SIGNALING IN THE ENDOTHELIAL DYSFUNCTION OF SYSTEMIC SCLEROSIS
F. Seguro Paula, M.C. Amaral, J. Delgado Alves

P.014 LYPOPHOSPHATIDIC ACID IS ELEVATED IN THE PLASMA OF PATIENTS WITH SCLERODERMA
S. Schoenfeld, E. Berdyshew, I. Bronova, V. Pace, A. Tager, F. Castelino
ENVIRONMENTAL FACTORS IN SYSTEMIC SCLEROSIS: A CASE-CONTROL STUDY

THE GLOBAL MICRORNA PROFILE OF SYSTEMIC SCLEROSIS WHOLE SKIN/DERMAL FIBROBLASTS AND THE ROLE OF THE XQ26.3 MICRNA CLUSTER AS A TGF-B PATHWAY POSITIVE FEEDBACK MECHANISM

IL-10-PRODUCING REGULATORY B CELLS ARE DECREASED AND NEGATIVELY ASSOCIATED WITH AUTOANTIBODY TITRES IN SYSTEMIC SCLEROSIS

EVALUATION OF FAT TISSUE AND PERITONEAL CIRCUMFERENCE, USING TRANSABDOMINAL SONOGRAPHY AND THEIR CORRELATION WITH DISEASE ACTIVITY AND INFLAMMATION IN SYSTEMIC SCLEROSIS PATIENTS
C. Rotondo, A. Chialà, M. Nivuori, M.G. Anelli, E. Praino, L. Coladonato, C. Fiorentini, G. Laselva, G. Lapadula, F. Iannone

EVALUATION OF SOLUBLE HLA-G IN SYSTEMIC SCLEROSIS
P. Contini, M. Borro, S. Negrini, G. Murdaca, F. Puppo

ANTIFIBROTIC EFFECTS OF THE TYROSINE KINASE INHIBITOR, BOSUTINIB, ON CULTURED NORMAL AND SYSTEMIC SCLEROSIS DERMAL FIBROBLASTS
S. Piera-Velazquez, F.A. Mendoza, K. Fasino, S.A. Jimenez

A LONGITUDINAL PILOT STUDY TO INVESTIGATE THE ROLE OF SELENIUM DEFICIENCY IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS
X. Pan, A. Marsden, J. Wilkinson, P. New, J. Manning, R. Unwin, G. Cooper, A. Herrick

TGFB DRIVEN EXPRESSION OF LONG NONCODING RNA H19X AS A KEY FACTOR IN SYSTEMIC SCLEROSIS AND OTHER FIBROTIC DISEASES

AMELIORATION OF SCLERODERMATOUS GRAFT VERSUS HOST DISEASE IN MICE BY BLOCKING STAT3 AND WNT/BETA-CATENIN PATHWAYS
F. Morin, N. Kavian, C. Nicco, C. Chereau, F. Batteux

SERUM CONCENTRATIONS OF 25-OH VITAMIN D IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS – A CROSS-SECTIONAL CLINICAL STUDY

PATHOGENIC OR CASUAL ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND FABRY DISEASE
C. Pintaudi, R. Cimino, S. Mazzuca

ASSOCIATION OF OCCUPATIONAL EXPOSURE WITH FEATURES OF SYSTEMIC SCLEROSIS
I. Marie

THE HOMEOPROTEIN TRANSCRIPTION FACTOR ENGRAILED-1 REGULATES CANONICAL TGFBETA SIGNALING SYSTEMIC SCLEROSIS
T. Mallano, K. Palumbo-Zerr, Ch. Beyer, C. Dees, J. Huang, Th. Wohlfahrt, G. Sceltt, J. Distler

INCREASED CD27 EXPRESSION IN THE SKIN AND SERA OF THE PATIENTS WITH SYSTEMIC SCLEROSIS
T. Makino, M. Jinnin, M. Nakayama, S. Fukushima, S. Masuguchi, H. Ihn

PREMATURE TELOMERE SHORTENING OF PERIPHERAL BLOOD LYMPHOCYTES IN SYSTEMIC SCLEROSIS

B CELLS SUBSETS AND CYTOKINES PRODUCTION IN SYSTEMIC SCLEROSIS

SIRT-1 REGULATES TGFBETA INDUCED DERMAL FIBROBLAST MIGRATION VIA MODULATION OF CYR61 EXPRESSION
H. Seo, E. Kwon, M. Cho, S. Lee, J. Kim

PAN PPAR AGONIST IVA337 HAS AN ANTI-FIBROTIC EFFECT IN MULTIPLE IN VITRO AND IN VIVO FIBROSIS MODELS

OCTREOTIDE AMELIORATES DERMAL FIBROSIS IN BLEOMYCIN-INDUCED SCLERODERMA
S. Koca, S. Orhan, S. Yolbas, A. Yildirim, A. Tektemur, I. H. Ozercan, E. Onalan

ACTIVATION OF THE TRANSIENT RECEPTOR POTENTIAL MELASTATINE 8 (TRPM8) RESULTS IN THE UPREGULATION OF FIBROTIC GENES EXPRESSION: POTENTIAL PATHWAY TO FIBROSIS IN SSC
B. Kahaleh, Y. Wang
INCREASED LEVELS OF LARGELY HYPMETHYLATED CIRCULATING DNA IN SYSTEMIC SCLEROSIS: A POTENTIAL DISEASE BIOMARKER
B. Kahaleh, N. Altorok, S. Nada, A. Al Harbi, Y. Wang

ENHANCED PROLIFERATION AND APOPTOSIS RESISTANCE OF SCLERODERMA DERMAL VASCULAR SMOOTH MUSCLE CELLS
B. Kahaleh, N. Altorok, S. Nada, A. Alharbi, Y. Wang

IL-9 OVER EXPRESSION AND TH9 POLARIZATION CHARACTERIZE SSC PATIENTS
G. Guggino, F. Ciccia, P. Cipriani, A. Rizzo, P. Di Benedetto, P. Ruscitti, V. Liakouli, A. Alessandro, G. Sireci, G. Triolo

ENERGY METABOLISM IN SKIN FIBROBLASTS FROM SCLERODERMA PATIENTS

AUTOPHAGOSOMES ARE ESSENTIAL FOR THE SECRETION OF TGF-BETA
B. Eckes, J. Nüchel, A. Zuk, K. Schönborn, G. Sengle, M. Plomann, T. Krieg

PERIPHERAL B LYMPHOCYTES SECRETE BOTH INTERLEUKIN 6 AND TRANSFORMING GROWTH FACTOR-BETA AND POTENTIATE FIBROBLASTS ACTIVATION IN SYSTEMIC SCLEROSIS

NKX2-5: A NOVEL LOCUS GENETICALLY ASSOCIATED WITH SCLERODERMA
A. Dritsoula, C. Fonseca, J. Martin, A. Herrick, C. Denton, M. Ponticos

PATHOGENETIC OVERLAP BETWEEN LOCALISED AND SYSTEMIC SCLEROSERMA: A STUDY OF NODULAR MORPHOEA IN SYSTEMIC SCLEROSIS
E. Derrett-Smith, N. Gak, S. Nihtyanova, V. Ong, V. Swale, C. Orteu, C. Denton

ORGAN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS IS PREDICTED BY NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS INDEPENDENT OF DISEASE-SPECIFIC AUTOANTIBODIES

EPIGENETIC REGULATION OF IL-6R BY MICRORNA-34A AND MICRORNA-155 IN SYSTEMIC SCLEROSIS
S. Alivernini, S. Bosello, B. Toluoso, S. Canestri, L. Bui, M. Fabrizi, G. Massi, I. McInnes, M. Kurowska-Stolarska, G. Ferraccioli

CHARACTERIZATION OF INFLAMMATORY CELL INFILTRATE OF SCLERODERMA SKIN: THE ROLE OF B CELLS IN SKIN PROGRESSION
S. Bosello, S. Alivernini, G. Lama, G. De Luca, G. Sica, G.F. Ferraccioli

IMMUNOPHENOTYPE CHARACTERIZATION OF SYSTEMIC SCLEROSIS PATIENTS: ASSOCIATED CLINICAL FEATURES AND PROGNOSTIC IMPLICATIONS
I. Cordeiro, A. Duarte, S. Sousa, L. Teixeira, J. Canas Da Silva, A. Cordeiro, M.J. Santos

LIPID Peroxidation, Antioxidant System and Immunological Status from the Children with Systemic Sclerosis
I. Chyzheuskaya, L. Belyaeva, L. Zajtseva, T. Yuraga, H. Hrustaleva, A. Lyatun

Characteristics of Systemic Sclerosis and Limited Scleroderma in Children
I. Chyzheuskaya, L. Belyaeva, L. Zajtseva, T. Yuraga, H. Hrustaleva, A. Lyatun

Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis
I. Chora, E. Romano, C. Mazzotta, M. Manetti, R. Costa, V. Machado, A. Cortez, S. Guiducci, R. Soares, M. Matucci-Cerinic

Chemerin: A Novel Marker of Early and Systemic Sclerosis?
C. Chighizola, E. Raschi, T. Schioppo, C. Artusi, F. Ingegnoli, M.O. Borghi, P.L. Meroni

Visfatin, Adiponectin, Leptin and IL-17 Serum Levels in Patients with Pericardial Effusion Related to Systemic Sclerosis

Analysis of Rare Protein and RNA Components Immunoprecipitated by Sera from Systemic Sclerosis Patients
A. Ceribelli, N. Isailovic, M. De Santis, E. Generali, M. Massarotti, M. Satoh, C. Selmi

Are Antinucleosome Antibodies Biomarkers of Microangiopathy in Systemic Sclerosis Patients?
E. Rezus, A. Cardoneanu, L.A. Macovei, C. Banu, A. Burlui

Occupational Exposure to Organic Solvents, Epoxy Resins and Silica Dust in Systemic Sclerosis Patients: Data from Two Romanian Centers
E. Rezus, A. Burlui, A. Cardoneanu, I.G. Stamate, M. Parvu
P.055 ASSOCIATION OF ANTI-PM/SCL ANTIBODY WITH RISK OF MALIGNANCY IN SCLERODERMA
C. Bruni, A. Lages, H. Patel, J. Harvey, V. Ong, M. Matucci-Cerinic, E. Derrett-Smith, C.P. Denton

P.056 TREATMENT WITH ABATACEPT PREVENTS EXPERIMENTAL DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED INFLAMMATION-DRIVEN FIBROSIS
M. Ponsoye, C. Frantz, N. Ruzehaji, M. Elhai, B. Ruiz, A. Cauvet, Y. Allanoire, J. Avouac

P.057 CHARACTERIZATION OF MICRO AND NANOPARTICLES AND QUANTIFICATION OF TRACE ELEMENTS IN SERUM AND HAIR SAMPLES OF SYSTEMIC SCLEROSIS PATIENTS
E. Artoni, G.L. Sighinolfi, M. Colaci, D. Giuggioli, C. Ferri

P.058 AN UNUSUAL PRESENTATION OF CALCIFICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS
J. Schollum, D. H. N. White, K. K. Solanki

P.059 RED BLOOD CELL DISTRIBUTION WIDTH AS A USEFUL INDICATOR TO PREDICT PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS
J. Zhao, H.N. Mo, Q. Wang, D. Xu, M.T. Li, X.F. Zeng

P.060 REVERSIBILITY OF PULMONARY ARTERIAL HYPERTENSION, ASSOCIATED WITH SYSTEMIC SCLEROSIS: CAN IT REALLY BE TRUE?
A. Volkov, E. Nikolaeva, I. Kurmukov, N. Yudkina

P.061 PULMONARY AND ACTIVATION REGULATED CHEMOKINE IS ASSOCIATED WITH EXTENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS

P.062 CXCL4: A POTENTIAL BIOMARKER FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE

P.063 INVESTIGATING MECHANISMS OF GENDER BIAS IN LUNG FIBROSIS USING MICE WITH SEX CHROMOSOME COMPLEMENT
I. Valera, S. Kafaja, B. Pham, R.R. Singh

P.064 ASSOCIATION OF THE HYPOXIA-INDUCIBLE FACTOR 1A (HIF1ALPHA) GENE POLYMORPHISM IN JAPANESE SYSTEMIC SCLEROSIS (SSC) WITH THE PULMONARY ARTERIAL HYPERTENSION (PAH)
K. Takagi, Y. Kawaguchi, M. Kawamoto, T. Higuchi, Y. Ichimura, H. Yamanaka

P.065 TROPISETRON ATTENUATES EXPERIMENTALLY INDUCED LUNG FIBROSIS AND FURTHER HIGHLIGHTS A POTENTIAL NEW TREATMENT STRATEGY AGAINST SCLERODERMA BY TARGETING ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS
A. Stegemann, C. Albrecht, T.A. Luger, M. Böhm

P.066 INTERSTITIAL LUNG DISEASE IN SCLERODERMA PORTUGUESE PATIENTS
S. Sousa, A. Duarte, I. Cordeiro, L. Teixeira, J. Canas da Silva, A. Cordeiro, M.J. Santos

P.067 DEFINING NOVEL FIBROBLAST SIGNALLING PATHWAYS IN PULMONARY FIBROSIS
X. Shiwen, E.A. Renzoni, M. Ponticos, C.P. Denton, A.U. Wells, D.J. Abraham

P.068 PROFILE AND PROGNOSIS OF PULMONARY ARTERIAL HYPERTENSION-associated with connective tissue diseases

P.069 RECURRING SPONTANEOUS PNEUMOTHORAX IN PATIENT WITH SYSTEMIC SCLEROSIS
M. Salgado, J. Vaz, L. Theilacker, F. Freire, S. Francisco, D. Sugui, R. Pereira Júnior, F. Bandeira, S. Hora

P.070 SCL-70 AUTOANTIBODY DETERMINED BY IMMUNODIFFUSION IS A CLINICAL PREDICTOR OF FASTER INTERSTITIAL LUNG DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS
G. Salazar, M. Fritzler, M. Hudson, C. Mejia Otero, R. Estrada-y-Martin, D. Nair, C. Pedroza, M. Mayes, S. Assassi
P.071  INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY, AND HEALTH (ICF) CORE SETS FOR CTD-ILD AND IDIOPATHIC PULMONARY FIBROSIS (IPF) – A NECESSARY MAP IN THE ERA OF ICD-11

P.072  MYCOPHENOLATE USE IN SYSTEMIC SCLEROSIS (SSC) PATIENTS WITH A DESIGNATION OF ‘PULMONARY HYPERTENSION (PH)’: FORCED VITAL CAPACITY (FVC), OUTCOMES AND SURVIVAL FROM THE EUSTAR DATABASE
L. Saketkoo, D. Huscher, C. Denton, G. Riemekasten, V. Steen, O. Distler

P.073  INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS - A DESCRIPTIVE STUDY
D. Rosa-Gonçalves, R. Fonseca, F. Aguiar, T. Martins-Rocha, M. Bernardes, L. Costa

P.074  ESOPHAGEAL DILATATION AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY
C. Richardson, J. Lee, O. Almagor, R. Nelson, J. Varga, M. Cuttica, J. D'Amico Dematte, R. Chang, M. Hinchcliff

P.075  IMPACT OF IMPAIRED RESPIRATORY MUSCLE STRENGTH ON DYSPNEA AND EXERCISE INTOLERANCE IN SYSTEMIC SCLEROSIS PATIENTS

P.076  CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY FINDINGS IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.077  UPREGULATION OF SERUM SCCA-IGM IN SCLERODERMA PATIENTS WITH REDUCED DLC0: A NEW BIOMARKER OF PULMONARY INVOLVEMENT

P.078  THE PROGNOSIS INTERVALS FOR PTS WITH SSC-ILD USING DISCRIMINANT ANALYSIS
O. Ovsyannikova, S. Glukhova, O. Koneva, V. Lesnyak, L. Ananieva

P.079  ASSESSMENT OF PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS

P.080  PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND THE ASSOCIATION WITH IMMUNOGLOBULIN A
K. Gunnarsson, S. Nygren, E. Svenungsson, A. Nordin

P.081  MODELLING OF LONGITUDINAL CHANGES IN LUNG FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND THEIR ASSOCIATION WITH DEVELOPMENT OF PULMONARY HYPERTENSION
S. Nihtyanova, V. Ong, C. Denton

P.082  COMBINED PULMONARY FIBROSIS AND EMPHYSEMA (CPFE) IN SYSTEMIC SCLEROSIS: A SYNDROME ASSOCIATED WITH HEAVY MORBIDITY AND MORTALITY

P.083  SURVIVAL IN SCLERODERMA PULMONARY ARTERIAL HYPERTENSION IN THE MODERN TREATMENT ERA: RESULTS FROM A LARGE MULTICENTRE AUSTRALIAN COHORT STUDY

P.084  RISK FACTORS FOR DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION IN AUSTRALIAN SCLERODERMA PATIENTS: RESULTS FROM A LARGE MULTICENTRE COHORT STUDY

P.085  SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD): PREDICTORS OF PROGRESSION OF ILD IN PATIENTS WITH SSC
A. Morais Castro, C. Resende, L. Ferreira, D. Moniz, C. Ponte, A. Pereira Da Silva

P.086  PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY INVOLVEMENT - CASES REVIEW
S. Martins, A. Sanches, R. Assis, R. Escoli, J. Garcia, M. Carvalho, F. Pimenta

P.087  DIAGNOSIS OF TRUE PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS REMAINS CHALLENGING: A SINGLE CENTRE EXPERIENCE
M. Luknar, P. Lesny, A. Tuchynova, J. Rovensky, E. Goncalvesova

P.088  MID-TERM EFFECTS OF RITUXIMAB IN CONNECTIVE TISSUE DISORDERS RELATED INTERSTITIAL LUNG DISEASE (ILD)
P.089 SERUM CONCENTRATION OF SP-D IN PATIENTS WITH SYSTEMIC SCLEROSIS AS POTENTIAL INDEX OF PULMONARY INVOLVEMENT  
E.J. Kucharz, A. Grosicka

P.090 THE IMPORTANCE OF HIGH RESOLUTION COMPUTED TOMOGRAPHY (HRCT) IN ASSESSMENT OF RITUXIMAB EFFICACY IN PATIENTS WITH INTERSTITIAL LUNG DISEASE (ILD) ASSOCIATED WITH SYSTEMIC SCLEROSIS (SSC)  

P.091 SERO-CONVERSION FROM ANTI-TH/TO TO ANTI-CENTROMERE ANTIBODIES IN A PATIENT WITH SYSTEMIC SCLEROSIS AND SEvere LUNG DISEASE  
M. Koenig, JL. Senecal, G. Perez, T. Camacho, A. Seaman, C. Bentow, M. Mahler

P.092 COEXISTENCE OF SYSTEMIC SCLEROSIS AND SARCOIDOSIS: A CASE REPORT  
S. Kobak, F. Sever, O. Sivrikoz, A. Karaarslan

P.093 THE EFFECT OF GASTROESOPHAGEAL REFLUX ON THE LUNG FUNCTION AND RADIOLOGIC FINDING IN PATIENTS WITH SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE  
H. Kim, J. Chae, H. Kim, S. Uh

P.094 THE ROLE OF LUNG ULTRASOUND FOR EVALUATION OF PULMONARY INVOLVEMENT (PULMOFIBROSIS) IN SYSTEMIC SCLEROSIS  
R. Karallilova, Y. Peeva, Z. Batalov, P. Selimov, S. Tsvetkova, A. Batalov

P.095 POTENTIAL BIOMARKERS FOR STRATIFICATION OF PULMONARY FIBROSIS IN SYSTEMIC SCLEROSIS  

P.096 EXHALED NITRIC OXIDE IN SYSTEMIC SCLEROSIS LUNG DISEASE  
N. K. Kojiz, J. T. Granton, P. E. Silkoff, J. Thenganatt, S. Chakravorty, S. R. Johnson

P.097 IMPACT OF SOCIOECONOMIC STATUS ON SURVIVAL IN CONNECTIVE TISSUE DISEASE ASSOCIATED AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION  

P.098 MORTALITY IN SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: SINGLE CENTER LONG-TERM EXPERIENCE WITH RISK ASSESSMENT ACCORDING TO THE NEW ESC/ERS GUIDELINES  
M. Inanc, G. Okumus, E. Oguz, M. Erdugan, A K Bilge

P.099 FREQUENCY OF PULMONARY MANIFESTATIONS IN SYSTEMIC SCLEROSIS WITH PULMONARY ARTERIAL HYPERTENSION  

P.100 PREVALENCE AND IMPACT OF PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS  

P.101 APPLICATION OF THE DETECT ALGORITHM IN A SINGLE CENTER  

P.102 DATA ABOUT PULMONARY HYPERTENSION IN THE SPANISH SCLERODERMA STUDY GROUP (SSSG) REGISTRY  

P.103 MOLECULAR PHENOTYPING OF ENDOTHELIAL CELLS ISOLATED DIRECTLY FROM THE PULMONARY ARTERIES OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION  
H. Farber, M. Trojanowska, S. Lenna, R. Lafyatis

P.104 HOW OFTEN DO WE NEED RIGHT HEART CATHETERIZATION IN THE FOLLOW-UP OF PATIENTS WITH SYSTEMIC SCLEROSIS?  

P.105 SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: IS IT FEASIBLE TO DIAGNOSE AND MAINTAIN PATIENTS IN WORLD HEALTH ORGANIZATION (WHO) FUNCTIONAL CLASS II?  
F. Dall’Ara, S. Zingarelli, M.G. Lazzaroni, M. Rossi, A. Tincani, P. Airò

P.106 PREVALENCE AND PREDICTORS OF PULMONARY ARTERIAL HYPERTENSION IN A COHORT OF SYSTEMIC SCLEROSIS  

P.107 MILD VS EXTENSIVE INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS (SSC): EXPERIENCE FROM A SINGLE CENTRE  
P.108 USEFULNESS OF BOSENTAN IN THE PREVENTION OF PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.109 AORTIC STENOSIS IS INCREASED IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION COMPARED TO OTHER TYPES OF PULMONARY HYPERTENSION
M. Martin, O. Olivas, A. Quezada, M. Rodriguez, C. Merino, C. Jimenez, P. Escribano, L. Carmona, P. Carreira

P.110 PERFORMANCE OF THE DETECT PROTOCOL FOR PULMONARY ARTERIAL DETECTION IN SYSTEMIC SCLEROSIS PATIENTS IN CLINICAL PRACTICE
O. Olivas, B. Joven, B. Diaz-Anton, C. Jimenez, M. Martin, P. Escribano, E. Loza, P. Carreira

P.111 A CASE OF SERONEGATIVE SYSTEMIC SCLEROSIS
L. Câmara, J. Oliveira, S. Pinheiro

P.112 NAILFOLD CAPILLAROSCOPY FINDINGS CAN HELP TO PREDICT THE PRESENCE AND SEVERITY OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves

P.113 SURVIVAL AND HEMODYNAMICS IN PATIENTS WITH SCLERODERMA ASSOCIATED PULMONARY VENOUS HYPERTENSION
K. Bourji, B. Kelemen, S. Mathai, E. Pigatto, E. Zanatta, F. Cozzi, P. Hassoun

P.114 DETECT ALGORITHM AND EARLY DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: A SINGLE CENTRE EXPERIENCE

P.115 DESIGN OF A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
O. Distler, J. Distler, K.K. Brown, V. Cottin, J. Varga, C. Coeck, H. Schmidt, K. Highland

P.116 CORRELATION BETWEEN THE SERUM LEVELS OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AND PULMONARY ARTERIAL PRESSURE IN A LONGITUDINAL COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
A. Belotti Masserini, F. Cagnoni, E. Bontempelli, C. Cavalleri, M. Destro
POSTER SESSION

CARDIAC

P.121 LEFT HEART DISEASE AS COMMON MANIFESTATION IN SYSTEMIC SCLEROSIS WITH PULMONARY HYPERTENSION

P.122 IMPACT OF CARDIAC MAGNETIC RESONANCE IMAGING WITH T1 MAPPING AND MULTI-B VALUE DIFFUSION-WEIGHTED SEQUENCES IN SYSTEMIC SCLEROSIS FOR THE ASSESSMENT OF MYOCARDIAL MICROSCOPIC FIBROSIS AND PERFUSION
B. Terrier, H. Gouya, A. Berezne, A. Regent, P. Cohen, L. Guillevin, C. Le Jeunne, P. Legmann, O. Vignaux, L. Mouton

P.123 CYCLOPHOSPHAMIDE CARDIOTOXICITY - A CLINICAL CASE.
L. Teixeira, F. Vinagre, J. Canas da Silva

P.124 A CASE OF ACUTE AND COMPLICATED HEART INVOLVEMENT IN PROGRESSIVE SYSTEMIC SCLEROSIS
G. Seskute, R. Rugiene, A. Cypiene, A. Laucevicius, I. Butrimiene

P.125 CORONARY MICROANGIOPATHY IN PATIENTS WITH SYSTEMIC SCLEROSIS: PROGRESSION AFTER 6 YEARS.

P.126 NT PROBNP LEVELS IN SYSTEMIC SCLEROSIS PATIENTS – A SUBCLINICAL NECESSITY
R. Nichitean, A. Petcu, S. Rednic

P.127 ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC SCLEROSIS AND THEIR ASSOCIATION WITH ISCHEMIC ARTERIAL EVENTS AND ATHEROSCLEROSIS
S. Coskun, E. Svenungsson, A. Antovic, K. Elvin, A. Nordin

P.128 VENTRICULAR ARRHYTHMIAS SUBSTRATE IN PATIENTS WITH SYSTEMIC SCLEROSIS

P.129 IS NT-PRO BNP A FUTURE ARRHYTHMIA MARKER IN PATIENTS WITH SYSTEMIC SCLEROSIS?
L. Muresan, A. Petcu, C. Pamfil, C. Muresan, M. Rinzis, D. Zdrenghea, S. Rednic

P.130 CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH ARRHYTHMIAS AND CONDUCTION DISORDERS
L. Muresan, A. Petcu, C. Pamfil, C. Muresan, M. Rinzis, D. Zdrenghea, S. Rednic

P.131 SERUM URIC ACID LEVEL, CARDIOVASCULAR RISK AND ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS
M. Madej, E. Morgiel, A. Luczak, P. Wojtala, P. Wiland

P.132 MYOCARDIAL FIBROSIS IN SYSTEMIC SCLEROSIS – ABOUT A NEW CASE.
O. Mkinsi

P.133 A SICK SINUS SYNDROME IN A PATIENT WITH SYSTEMIC SCLEROSIS
S.O. Jung, Y.S. Kim, H.S. Kim

P.134 SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS: NOT LESS FREQUENT THAN RHEUMATOID ARTHRITIS AND NOT DETECTED WITH CARDIOVASCULAR RISK INDICES

P.135 FREQUENCY OF CARDIAC MANIFESTATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY ARTERIAL HYPERTENSION

P.136 RIGHT VENTRICULAR INVOLVEMENT IN A PATIENT WITH SYSTEMIC SCLEROSIS MIMICKING ARRHYTHMOCENIC RIGHT VENTRICULAR CARDIOMYOPATHY
A. Akdogan, A. Erden, L. Kilic, L. Sahiner, I. Ertelen

P.137 EVALUATING CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH SYSTEMIC SCLEROSIS
R. Encarnado Assis, S. Cunha Martins, A. R. Sanches, J. Garcia, M. Carvalho, F. Pimenta

P.138 CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS – A PORTUGUESE REALITY
A. Duarte, I. Cordeiro, S. Sousa, L. Teixeira, J. Canas Da Silva, A. Cordeiro, M.J. Santos
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.142</td>
<td>RISK FACTORS FOR THE DEVELOPMENT OF GANGRENE IN SYSTEMIC SCLEROSIS PATIENTS WITH DIGITAL ULCER DISEASE: DATA FROM THE DUO REGISTRY</td>
<td>Y. Allanore, C.P. Denton, T. Krieg, P. Cornelisse, D. Rosenberg, B. Schwierin, M. Matucci-Cerinic</td>
</tr>
<tr>
<td>P.143</td>
<td>PATIENTS’ PERSPECTIVES ON LIVING WITH SYSTEMIC SCLEROSIS: A SEMI-STRUCTURED INTERVIEW STUDY</td>
<td>D. Sumpton, V. Thakkar, S. O’Neill, D. Singh-Grewal, J. Craig, A. Tong</td>
</tr>
<tr>
<td>P.145</td>
<td>LATE-ONSET SYSTEMIC SCLEROSIS: CLINICAL PICTURE AND OUTCOME</td>
<td>C. Stagnaro, A. D’Ascanio, A. Della Rossa, M. Mosca</td>
</tr>
<tr>
<td>P.148</td>
<td>EVOLUTION OF SYMPTOMS IN LIMITED AND DIFFUSE FORMS OF SYSTEMIC SCLEROSIS (RESULTS OF FIVE-YEAR STUDY)</td>
<td>V. Semenov, T. Lysunets, O. Kuryata</td>
</tr>
<tr>
<td>P.149</td>
<td>THE FREQUENCY OF SECONDARY SJOGREN SYNDROME IN SCLERODERMA</td>
<td>P. Wiland, A. Sebastian, A. Szachowicz, P. Woytala, E.J. Mroczek</td>
</tr>
<tr>
<td>P.150</td>
<td>SURVIVAL, CAUSES OF DEATH AND PROGNOSIS FACTORS IN SYSTEMIC SCLEROSIS IN ARGENTINA</td>
<td>P. Sansinane, J. Marcos, A. Salas, C. Costi, C. Pena, M. Garcia</td>
</tr>
<tr>
<td>P.152</td>
<td>CAN THE SELF-EFFICACY TO MANAGE CHRONIC DISEASE SCALE BE USED TO EVALUATE SELF-EFFICACY IN PATIENTS WITH SYSTEMIC SCLEROSIS? A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK COHORT STUDY</td>
<td>K.E. Riehm, L. Kwakkenbos, M. Carrier, W. Nielsen, K. Nielsen, B.D. Thoms</td>
</tr>
<tr>
<td>P.153</td>
<td>DEMOGRAPHIC AND DISEASE CORRELATES OF CLINICALLY SIGNIFICANT FATIGUE IN SYSTEMIC SCLEROSIS: PRELIMINARY EVIDENCE USING CASE-DEFINITION CRITERIA</td>
<td>D.B. Rice, L. Kwakkenbos, R. Steele, M. Hudson, M. Baron, B.D. Thoms, Canadian SSc Research Group</td>
</tr>
<tr>
<td>P.154</td>
<td>MORTALITY ANALYSIS IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS</td>
<td>R. Paz, R. Sousa Almeida, A. Alves Oliveira, P. M. Pego, Y. Abuowda, C. Santos, J. Matos Costa</td>
</tr>
<tr>
<td>P.155</td>
<td>THE EPIDEMIOLOGY OF SCLERODERMA IN NORTHWESTERN PART OF TURKEY: 12 YEARS’ FOLLOW-UP DATA</td>
<td>O. Pamuk, S. Donmez</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P.156</td>
<td>SYSTEMIC SCLEROSIS PATIENTS ON INTENSIVE CARE UNIT - REASONS FOR ADMISSION AND DETERMINANTS OF OUTCOME</td>
<td>S. Nihtyanova, F. Figorilli, R. Sinharay, C. Denton, B. Agarwal, V. Ong</td>
</tr>
<tr>
<td>P.157</td>
<td>NURSE-LED RAPID ACCESS DIGITAL ULCER CLINIC: AN AUDIT OF UK PATIENT COHORT EXPERIENCE</td>
<td>T. Ngcozana, C.P. Denton, V. Ong</td>
</tr>
<tr>
<td>P.164</td>
<td>FATIGUE IN SCLERODERMA: A CANADIAN SCLERODERMA RESEARCH GROUP STUDY INVESTIGATING SOCIODEMOGRAPHIC AND DISEASE CORRELATES</td>
<td>B. Levis, L. Kwakkenbos, M. Hudson, M. Baron, B.D. Thombs</td>
</tr>
<tr>
<td>P.167</td>
<td>JUVENILE LIMITED SCLERODERMA IN ONE PAEDIATRIC RHEUMATOLOGY CENTRE IN THE UNITED ARAB EMIRATES</td>
<td>K. Khawaja, M. Almaini</td>
</tr>
<tr>
<td>P.171</td>
<td>THE EXPERIENCE OF LIVING WITH VISIBLE DIFFERENCES FROM SCLERODERMA</td>
<td>L. Jewett, V.C. Delisle, V.L. Malcarne, S. Peláez, M. Hudson, B.D. Thombs</td>
</tr>
</tbody>
</table>
INCIDENCE AND PREDICTORS OF CUTANEOUS MANIFESTATIONS DURING THE EARLY COURSE OF SYSTEMIC SCLEROSIS - A 10 YEAR LONGITUDINAL STUDY FROM THE EUSTAR DATABASE  

CANCER RISK IN EGYPTIAN PATIENTS WITH SYSTEMIC SCLEROSIS  
M. Hassanien, G. Husein, N. Mohamed

SYSTEMIC SCLEROSIS INPATIENT MORTALITY HAS NOT IMPROVED FROM 1995-2011. RESULTS FROM A NATIONAL IRISH AUDIT OF SCLERODERMA CO-MORBIDITIES  
L. Harty, D. Fitzgerald, J. Ryan, M. Henry, S. Harney

EXPLORING THE SOURCES OF EMOTIONAL DISTRESS AND MANAGEMENT STRATEGIES AMONG PEOPLE LIVING WITH SCLERODERMA THROUGH FOCUS GROUPS: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK STUDY  
S. Gumuchian, V. Delisle, S. Peláez, M-E. Carrier, L. Jewett, G. El-Baalbaki, L. Kwakkenbos, B. Thoms, S. Bartlett

CLINICAL AND IMMUNOLOGICAL FEATURES IN A COHORT OF 228 SYSTEMIC SCLEROSIS  
C. Grange, C. Mausservey, C. Khouatra, D. Jullien, P. Seve, N. Fabien, J.C. Lega, A. Hot

RESTLESS LEG SYNDROME PREVALENCE IS NOT INCREASED IN SYSTEMIC SCLEROSIS PATIENTS  

A PSYCHOMETRIC ANALYSIS OF THE SOCIAL INTERACTION ANXIETY SCALE (SIAS-6) IN SYSTEMIC SCLEROSIS: RESULTS FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT  

VALIDATION OF A ROMANIAN VERSION OF DURUÖZ HAND INDEX QUESTIONNAIRE FOR PATIENTS WITH SYSTEMIC SCLEROSIS  

DEVELOPMENT OF A JUVENILE SYSTEMIC SCLEROSIS RESPONSE INDEX (JSSRI)  

PERFORMANCE OF THE ADULT SYSTEMIC SCLEROSIS CLASSIFICATION IN JUVENILE SYSTEMIC SCLEROSIS PATIENTS. RESULTS FROM THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT – WWW.JUVENILE-SCLERODERMA.COM  

IS THERE A DIFFERENCE IN THE PRESENTATION OF DIFFUSE AND LIMITED SUBTYPE OF JUVENILE SYSTEMIC SCLEROSIS IN CHILDHOOD? RESULT FROM THE JUVENILE SCLERODERMA INCEPTION COHORT WWW.JUVENILE-SCLERODERMA.COM  

UPDATE ON THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT PROJECT. CHARACTERISTICS OF THE FIRST 50 PATIENTS AT FIRST ASSESSMENT. WWW.JUVENILE-SCLERODERMA.COM  

PREVALENCE OF ANXIETY AND DEPRESSION IN A SYSTEMIC SCLEROSIS COHORT  

FATIGUE, BUT NOT SLEEP, IS A PROBLEM IS SYSTEMIC SCLEROSIS PATIENTS  

MALIGNANT NEOPLASTIC DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS  

DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) REFERRAL AND DIAGNOSIS: RESULTS OF A SURVEY OF HEALTHCARE PROVIDERS  
P.189  PATIENT PERCEPTION OF DISEASE BURDEN IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)  

P.190  THE EXPERIENCE OF BEING DIAGNOSED AND LIVING WITH SCLERODERMA: IMPROVING COMMUNICATION BETWEEN PATIENTS AND HEALTH CARE PROFESSIONALS  
V. Delisle, L. Jewett, V. Malcarne, M. Hudson, B. Thombs

P.191  THE SCLERODERMA SUPPORT GROUP SURVEY: UNDERSTANDING PEOPLE’S EXPERIENCES WITH SCLERODERMA SUPPORT GROUPS  
V. Delisle, S. Gumuchian, V. Malcarne, G. El-Baalbaki, S. Pelaez, B. Thombs

P.192  ANOSMIA HERALDING THE ONSET OF MIXED CONNECTIVE TISSUE DISEASE IN A PATIENT WITH SYSTEMIC SCLEROSIS  

P.193  PSYCHOLOGICAL DIMENSIONS IN SCLERODERMA: SYMPTOMS, REPRESENTATION OF DISEASE, SOCIAL SUPPORT, PERCEPTION OF PAIN  
P. Colombelli, F. Pierazzuoli, E. Gatti, A. Belotti Masserini, F. Cagnoni, G.P. Dognini, A. Besozzi, M. Destro

P.194  SYSTEMIC SCLEROSIS AND CANCER: THE EXPERIENCE OF AN ITALIAN TERTIARY REFERRAL RHEUMATOLOGY CENTRE  
M. Colaci, C. Vacchi, A. Manfredi, M. Sebastiani, D. Giuggioli, C. Ferri

P.195  AN INTERNATIONAL COLLABORATION TO COLLECT DATA AND DEVELOP ONLINE INTERVENTIONS FOR SCLERODERMA PATIENTS AND AN UPDATE FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN)  
M. Carrier, L. Kwakkenbos, B. Thombs, SPIN Investigators

P.196  SYSTEMIC SCLEROSIS IS ASSOCIATED WITH POOR SLEEP QUALITY AND DECREASED QUALITY OF LIFE  
V. C Romão, M.J. Gonçalves, A. Castro, C. Ponte, H. Canhão, C. Resende, J.A. Pereira Da Silva

P.197  VASCULOPATHY AND DISABILITY IN SYSTEMIC SCLEROSIS PATIENTS TREATED WITH BOSENTAN  
E. Rezus, A. Burlui, A. Cardoneanu, C. Banu

P.198  SHORT TERM NAILFOLD VIDEOCAPILLAROSCOPY (NVC) EVALUATION MAY NOT REFLECT DIGITAL ULCERS (DU) CHANGES IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)  

P.199  PATIENT- REPORTED OUTCOMES REFLECT CHANGES IN DIGITAL ULCER (DU) STATUS IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)  

P.200  ACCESSIBILITY AND ADHERENCE IN PATIENTS WITH SCLERODERMA RESIDENTS IN BUENOS AIRES  
C. Bento, A. Cusa

P.201  MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS- A SINGLE CENTER EXPERIENCE  
A. Balbir-Gurman, H. Attamna, D. Markovits, M. Nahir, N. Schultz, V. Shataylo, Y. Braun-Moscovici

P.202  EXERCISE HABITS AND ASSOCIATED FACTORS IN SCLERODERMA: A SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN) COHORT STUDY  
M. Azar, D. Rice, L. Kwakkenbos, M.E. Carrier, I. Shrier, M. Hudson, B. Thombs, SPIN Investigators

P.203  EXPLORING THE PHYSICAL AND PSYCHOSOCIAL FACTORS THAT IMPACT QUALITY OF LIFE IN SYSTEMIC SCLEROSIS (SSC)  
B. Alcacer-Pitarch, A. Redmond, M. Buch, F. Del Galdo, AM. Keenan

P.204  HIGH RESOLUTION MANOMETRY FACE TO FACE WITH THE THE SSC_GIT 1.0 QUESTIONNAIRES IN SYSTEMIC SCLEROSIS PATIENTS  
H. Abozaid, H. Imam, M. Abdelaziz, D. El Hammady, N. Fathi

P.205  THE ERASMUS SYNDROME : EXPOSURE TO SILICA AND SYSTEMIC SCLEROSIS  
A. Abdessemed, S. Slimani, N. Khaldoun, F. Bougrina, S. Bencheikh, N. Ait Belabas, A. Djoudi, N. Brahimi, A. Ladjouze

P.206  CANCER AND SYSTEMIC SCLEROSIS  
A. Abdessemed, N. Khaldoun, A. Djoudi, N. Ait Belabas, F. Bougrina, N. Brahimi, L. Aladjouze
POSTER SESSION

IMAGING

P.207  PRELIMINARY MUSCULOSKELETAL ULTRASOUND (MSUS) ULCER DEFINITION DOES NOT CORRELATE WITH VISUAL OBSERVATION IN SYSTEMIC SCLEROSIS (SSC) PATIENTS

P.208  MUSCULOSKELETAL ULTRASOUND FINDINGS IN SYSTEMIC SCLEROSIS: CORRELATION WITH CLINICAL ASPECTS AND SEROLOGICAL BIOMARKERS

P.209  COMPARISON OF SYNOVIAL INFLAMMATION BETWEEN SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS BY MAGNETIC RESONANCE IMAGING OF HANDS

P.210  QUANTIFYING DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: REPEATABILITY AND REPRODUCIBILITY OF SOFTWARE-BASED SURFACE AREA MEASUREMENT
V. Simpson, G. Dinsdale, M. Hughes, A.L. Herrick

P.211  ASSESSMENT OF BONE INVOLVEMENT OF DISTAL FOREARM BY HR-PQCT IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS

P.212  COMPARISON BETWEEN MODIFIED RODNAN SKIN SCORE AND HIGH-FREQUENCY SKIN ULTRASOUND IN EARLY IDENTIFICATION OF SKIN ININVOLVEMENT IN SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro, A. Sulli, E. Bernero, M.A. Cimmino, E. Alessandri, M. Cutolo

P.213  SONOGRAPHY SIGNS OF INTERSTITIAL LUNG DISEASE RELATED WITH SYSTEMIC SCLEROSIS EVALUATED BY CHEST ULTRASOUND: A COMPARISON BETWEEN HONEYCOMBING AND GROUND GLASS HIGH RESOLUTION CHEST CT FINDINGS
C. Rotondo, A. Chialà, M.G. Anelli, M. Nivuori, L. Coladonato, C. Fiorentini, S. Perniola, G. Lapadula, F. Iannone

P.214  ECHOSONOGRAPHY OF SKIN FINGERS IN PATIENTS WITH SYSTEMIC SCLEROSIS
S. Prodanovic, G. Radunovic, N. Damjanov

P.215  COMPARISON OF LASER SPECKLE CONTRAST ANALYSIS AND CAPILLAROSCOPY IN SYSTEMIC SCLEROSIS PATIENTS WITH DIGITAL ULCERS
R. Cimino, C. Pintadi, S. Mazzuca

P.216  CAPILLAROSCOPIC ALTERATIONS IN DERMATOMYOSITIS AND SYSTEMIC SCLEROSIS: TOWARDS IDENTIFICATION OF SPECIFIC PATTERNS
A. Manfredi, M. Sebastiani, F. Campomori, N. Pipitone, D. Giuggioli, M. Colaci, C. Ferri

P.217  ULTRASONOGRAPHIC FEATURES IN THE HAND OF PATIENTS WITH SYSTEMIC SCLEROSIS REFLECT VISCERAL MANIFESTATIONS OF THE DISEASE
G. Coiffier, A. Lescoat, J.D. Albert, C. Driotcourt, C. Cazalets, P. Jego, A. Perdriger

P.218  ULNAR ARTERY OCCLUSION ASSESSED BY POWER DOPPLER ULTRASOUND IS ASSOCIATED WITH ACROOSTEOLYSIS IN SYSTEMIC SCLEROSIS
A. Lescoat, G. Coiffier, J.D. Albert, C. Driotcourt, C. Cazalets, A. Perdriger, P. Jego

P.219  RELIABILITY OF THE QUANTITATIVE ASSESSMENT OF PERIPHERAL BLOOD PERFUSION BY LASER SPECKLE CONTRAST ANALYSIS IN A SYSTEMIC SCLEROSIS COHORT
V. Lambrecht, M. Cutolo, F. De Keyser, S. Decuman, B. Ruaro, A. Sulli, E. Deschepper, V. Smith

P.220  TRANSITIONAL CHANGES IN THE INTERSTITIAL LUNG DISEASE USING HIGH RESOLUTION COMPUTED TOMOGRAPHY
G. Kim, J. Goldin, M. Brown, P. Lo, P. Lu, D. Tashkin

P.221  INVOLVEMENT OF JOINT AND TENDON IN SYSTEMIC SCLEROSIS

P.222  IS THERE CORRELATION BETWEEN DERMAL THICKNESS AND PULMONARY INVOLVEMENT IN EARLY DIFFUSE SYSTEMIC SCLEROSIS? – THE ROLE OF ULTRASOUND
R. Karalilova, Yu Peeva, Z. Batalov, P. Selimov, S. Tsvetkova, A. Batalov

P.223  CLINICAL APPLICATIONS OF NAILFOLD CAPILLAROSCOPY IN A GENERAL RHEUMATOLOGY SERVICE
F. Haji, S. Donnelly, G. McCarthy, C.J. Mccarthy
POSTER SESSION

P.224 CAPILLAROSCOPY IN DAY-TO-DAY PRACTICE - QUALITATIVE OR SEMIQUANTITATIVE CAPILLAROSCOPIC SCORING FOR SCLERODERMA PATIENTS?

P.225 RELATION BETWEEN QUALITATIVE AND SEMIQUANTITATIVE CAPILLAROSCOPIC ASSESSMENT AND DISEASE DURATION IN SYSTEMIC SCLEROSIS

P.226 MOBILE PHONE PHOTOGRAPHS IN THE OBJECTIVE ASSESSMENT OF RAYNAUD’S PHENOMENON

P.227 LONG-TERM DURATION SYSTEMIC SCLEROSIS - WE NEED A RECLASSIFICATION OF CAPILLAROSCOPY PATTERNS. A MULTICENTER STUDY

P.228 CAPILLAROSCOPIC PATTERN AND ORGAN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
E. Rezus, A. Burlui, A. Cardoneanu

P.229 AN EULAR STUDY GROUP PILOT STUDY ON RELIABILITY OF “SIMPLE” CAPILLAROSCOPIC DEFINITIONS TO DESCRIBE CAPILLARY MORPHOLOGY IN RHEUMATIC DISEASES

P.230 NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS ASSOCIATED WITH CALCINOSIS AND ACRO-OSTEOLYSIS IN SYSTEMIC SCLEROSIS
J. Avouac, L. Morardet, M. Sammour, A. Kahan, A. Feydy, Y. Allano
THE EFFICACY AND SAFETY OF BOSENTAN TREATMENT IN SCLERODERMA PATIENTS WITH DIGITAL ULCERS
S. Ugurlu, B. Ergezen, S. Baykal, D. Cevirgen

NAILFOLD CAPILLARY DILATIONS IN PATIENTS WITH RAYNAUD’S PHENOMENON MIGHT ANTICIPATE THE IDENTIFICATION OF THE EARLY SCLERODERMA CAPILLAROSCOPY PATTERN: A CASE-CONTROL STUDY
A. Trombetta, A. Sulli, C. Pizzorni, B. Ruaro, S. Paolino, V. Smith, E. Alessandri, M. Cutolo

DIGITAL ULCERS IN SYSTEMIC SCLEROSIS AND THE CUTANEOUS SUBSETS: CLINICAL, IMMUNOLOGICAL, NAILFOLD CAPILLAROSCOPY, AND SURVIVAL DIFFERENCES IN THE SPANISH RESCLE REGISTRY
C. Tolosa, ML. Morera, B. Marí, A. Guillén, N. Ortego, M. Rubio, L. Trapiella, M. Rodriguez, A. Marin, C. Simeón, On behalf of RESCLE

NAILFOLD CAPILLAROSCOPY FINDINGS IN SCLERODERMA PATIENTS – PROGNOSTIC IMPLICATIONS
L. Teixeira, I. Cordeiro, S. Sousa, A.C. Duarte, J. Canas da Silva, A. Cordeiro, M. José Santos

SAFETY AND EFFICACY OF BOSENTAN TREATMENT IN JAPANESE PATIENTS WITH DIGITAL ULCERS ASSOCIATED WITH SYSTEMIC SCLEROSIS
K. Takehara and Du Clinical Trial Group In Japan

INTERPLAY OF OSTEOPROTEGERIN (OPG)/RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KB LIGAND (RANKL) MOLECULES AS VASCULAR MARKERS IN SYSTEMIC SCLEROSIS

SYSTEMIC SCLEROSIS: ABOUT A PROSPECTIVE SERIES OF 60 PATIENTS
D. Si Ahmed, F. Haddoum, M. Bouali -Benhalima, F. Bouali

CLINICO-HISTOPATHOLOGIC SURVEY OF THE PATIENTS WITH SCLERODERMA-LIKE DISORDER: CASES REVIEW
H. Seo, E. Kwon, M. Cho, S. Lee, J. Kim

SYSTEMIC SCLEROSIS-LIKE NAILFOLD VIDEOCAPILLAROSCOPY CHANGES IN GENETIC MYOPATHIES
F. Seguro Paula, I.A. Ferreira, M.C. Amaral, A. Valverde, J. Delgado Alves

AN ECHOCOLOR-DOPPLER STUDY IN SYSTEMIC SCLEROSIS: ARE SYNTHETIC ANALOGUES OF PROSTACYCLIN PROTECTIVE FOR ENDOTHELIAL DYSFUNCTION OF LARGE VESSELS?
I. Sciarra, M. Caucci, K. Stefanantoni, M. Vasile, N. Iannace, A. Scarno, G. Valesini, V. Ricciери

CAROTID DOPPLER ULTRASOUND AS SCREENING FOR CARDIOVASCULAR RISK IN PATIENTS WITH SYSTEMIC SCLEROSIS

DEVELOPMENT OF THE MAWSLEY CALCINOSIS QUESTIONNAIRE (MCQ) VERSION 1 - A PATIENT-REPORTED OUTCOME MEASURE (PROM) FOR SYSTEMIC SCLEROSIS RELATED CALCINOSIS (SSC-CA)
L. Saketkoo, K. Fligelstone, E. Busman, A. Christensen, S. Khaliqeu, S. Cenac, A. Aubin, A. Mawdsley, J. Gordon, R. Kaufman, M. Baron, V. Steen, T. Frech

EVALUATION OF SKIN BLOOD PERFUSION BY LASER SPECKLE CONTRAST ANALYSIS IN PRIMARY RAYNAUD’S PHENOMENON AND SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro, A. Sulli, V. Smith, AC. Trombetta, S. Paolino, C. Pizzorni, M. Cutolo

CAN ALTERED HEMORHEOLOGY CONTRIBUTE TO MICROVASCULAR DAMAGE IN SYSTEMIC SCLEROSIS?

AN INTERNAL MEDICINE DEPARTMENT’S EXPERIENCE WITH ILOPROST
R. Ribeiro, M. Silva, J. Oliveira, P. Barreto, S. Pinheiro

IMMEDIATE IMPROVEMENTS IN HAND PUFFINESS & MOBILITY IN SCLERODERMA FOLLOWING ILOPROST INFUSIONS
C. Rajapakse

EFFECT OF BOSENTAN ON THE MICROCIRCULATION CAPILLARY FLOW IN PATIENTS WITH SYSTEMIC SCLEROSIS AND DIGITAL ULCERS: CAPILLAROSCOPIF ANALYSIS OF 6 PATIENTS
POSTER SESSION

P.248 SYSTEMIC SCLEROSIS AND THE VASOREACTIVITY OF CEREBRAL MICROCIRCULATION
E. Morgiel, M. Nowakowska-Kotas, M. Madej, R. Podemski, P. Wiland

P.249 ANTI-PHOSPHOLIPID ANTIBODIES IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS – A CROSS-SECTIONAL CLINICAL STUDY

P.250 PREDICTIVE VALUE OF ALLEN TEST FOR THE OCCURRENCE OF NEW DIGITAL ULCER IN SSC-PATIENTS
R. Cimino, C. Pintaudi, S. Mazzuca

P.251 OUTCOME AND MANAGEMENT OF SSC-PATIENTS WITH DIGITAL ULCERS (DU) IN A SINGLE CENTRE (N° 334) OF DUO REGISTRY.
C. Pintaudi, R. Cimino, S. Mazzuca

P.252 BONE MARROW-DERIVED MESENCHYMAL STEM CELLS (MSC) FROM SYSTEMIC SCLEROSIS (SSC) EXPRESS LOW LEVELS OF CD13: A POSSIBLE EXPLANATION FOR IMPAIRED ABILITY TO DIFFERENTIATE TOWARD THE ENDOTHELIAL LINEAGE?
C. Mazzotta, M. Manetti, E. Romano, I. Rosa, L. Ibba-Manneschi, S. Bellando-Randone, S. Guiducci, M. Matucci-Cerinic

P.253 INFRARED THERMOGRAPHY AFTER COLD CHALLENGE: VALIDATION IN DIAGNOSIS OF RAYNAUD’S PHENOMENON IN PEDIATRIC AGE
G. Martini, M. Cappella, R. Culpo, M. Sprocati, A. Meneghel, F. Zulian

P.254 SCLERODERMA WITH PSEUDAINHUM
M. Marques Silva, R. Ribeiro, J. Oliveira

P.255 VASCULAR EVALUATION OF THE HAND BY POWER DOPPLER ULTRASONOGRAPHY PROVIDES NEW PREDICTIVE MARKERS OF ISCHEMIC DIGITAL ULCERS IN SYSTEMIC SCLEROSIS.
A. Lescoat, G. Coiffier, A. Rouil, C. Droitcourt, C. Cazalets, A. Perdriger, P. Jego

P.256 PERIPHERAL VASOCONSTRICTION INDUCED BY BETA-BLOCKERS: A SYSTEMATIC REVIEW AND A NETWORK META-ANALYSIS.
C. Khouri, T. Jouve, S. Blaise, P. Carpentier, J.L. Cracowski, M. Roustit

P.257 SEASONAL VARIATION OF RAYNAUD’S PHENOMENON AND DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A MULTICENTER LONGITUDINAL STUDY

P.258 COMPARISON OF ULNAR ARTERY VASCULOPATHY IN CONNECTIVE TISSUE DISEASES
J. Jun, T. Kim, S. Song, H. Ahn, S. Bae, Y. Sung

P.259 DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN SYSTEMIC SCLEROSIS
N. Hakami, S. Johnson

P.260 CONTRIBUTION OF NAILFOLD VIDEOCAPILLAROSCOPY TO THE DIAGNOSIS OF SYSTEMIC SCLEROSIS IN THE JAPANESE POPULATION
Y. Ichimura, Y. Kawaguchi, K. Takagi, A. Tochimoto, T. Higuchi, Y. Katsumata, H. Yamanaka

P.261 DIGITAL ULCERS IN SYSTEMIC SCLEROSIS ARE ASSOCIATED WITH MICROANGIOPATHIC ABNORMALITIES OF PERILESIONAL SKIN AS ASSESSED BY CAPILLAROSCOPY
M. Hughes, T. Moore, J. Manning, G. Dinsdale, A. Murray, A. Herrick

P.262 THERMOGRAPHIC ABNORMALITIES PREDICT FUTURE DIGITAL ULCERS AND DEATH IN PATIENTS WITH SYSTEMIC SCLEROSIS
M. Hughes, J. Wilkinson, T. Moore, J. Manning, P. New, G. Dinsdale, A. Murray, A. Herrick

P.263 CRITICAL DIGITAL ISCHAEMIA IN SYSTEMIC SCLEROSIS: THE IMPORTANCE OF REMEMBERING THERE IS A DIFFERENTIAL DIAGNOSIS
C.A Sharp, Q. Akram, M. Hughes, L. Muir, A.L. Herrick

P.264 NON-INVASIVE OXYGEN-OZONE THERAPY IN THE TREATMENT OF DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS
M. Hassanien, S. Rashad, A. Algohe, A. Awamy, N. Mohamed

P.265 CENTRAL NERVOUS SYSTEM INVOLVEMENT IN SYSTEMIC SCLEROSIS

P.266 SYSTEMIC SCLEROSIS ASSOCIATED TO ESSENTIAL THROMBOCYTHEMIA CAUSING SEVERE DIGITAL ISCHEMIA

P.267 A PILOT STUDY ON SOLUBLE (PRO)RENIN RECEPTOR IN PATIENTS WITH SYSTEMIC SCLEROSIS
M. Gorga, A.M. Soare, A.M. Gherghe, R. Dobrota, C. Mambet, C. Mihai

P.268 DIGITAL ULCER SCORE - A SCORING SYSTEM TO ASSESS DIGITAL ULCERS IN PATIENTS SUFFERING FROM SYSTEMIC SCLEROSIS
H. Gil, E. Siegert, D. Tomsitz, K. Mattat, C. March, G. Riemekasten, M. Worm
CORRELATION BETWEEN NAILFOLD MICROANGIOPATHY SEVERITY AND MACROVASCULAR DISEASE IN SYSTEMIC SCLEROSIS PATIENTS

THE INFLUENCE OF IMMUNOSUPPRESSIVE THERAPY ON MICROANGIOPATHY IN SYSTEMIC SCLEROSIS AS MEASURED WITH NAILFOLDCAPILLAROSCOPY
J. Meijs, B. de Boer, A.A. Schouffoer, T.W.J, Huizinga, H. Putter, J.K. de Vries-Bouwstra

INTIMA-MEDIA THICKNESS EVALUATION AND CARDIOVASCULAR RISK ESTIMATION IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS

TREPROSTINIL IONTOPHORESIS IMPROVES DIGITAL BLOOD FLOW DURING LOCAL COOLING IN SYSTEMIC SCLEROSIS
J. Cracowski, F. Gaillard-Bigot, S. Blaise, C. Cracowski, C. Seinturier, B. Imbert, P. Carpentier, M. Roustit

OLIGOSYMPOMATIC PULMONARY EMBOLISM IN SYSTEMIC SCLEROSIS PATIENTS

MICROVASCULATURE CHANGES AND ANGIGENIC FACTORS IN SYSTEMIC SCLEROSIS - DATA FROM A SINGLE CENTER REGISTRY

SKIN TELANGIECTASIA IDENTIFY A SUBSET OF SYSTEMIC SCLEROSIS PATIENTS WITH SEVERE VASCULAR DISEASE
J. Avouac, C. Hurabielle, G. Lepri, T. De Risi, A. Kahan, Y. Allanore

ABNORMAL LIPID PROFILE AS A RISK FACTOR FOR ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS: RESULTS FROM A MULTICENTRIC EUSTAR COHORT

MICROVASCULAR ANGINA IN SYSTEMIC SCLEROSIS
I. Aleksic, B. Stamenkovic, M. Deljinin Ilic, S. Milenkovic

JUVENILE-ONSET SYSTEMIC SCLEROSIS WITH SEVERE VASCULAR LESIONS AND MILD EVIDENCE OF ORGAN-SPECIFIC INVOLVEMENT: A CASE REPORT
S. Agachi, L. Groppa, S. Popa, I. Pirlog

HEALING OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: REAL LIFE DATA FROM THE DESSCIPHER OBSERVATIONAL STUDY OF THE EUSTAR GROUP

MULTICENTER OBSERVATIONAL STUDY OF THE REPERCUSSIONS OF DIGITAL ULCERS ON FUNCTIONAL DISABILITY AND WORK AND DAILY ACTIVITIES IN PATIENTS WITH SYSTEMIC SCLEROSIS: LAUTES STUDY
I. Castellví, S. Eguiluz, V. Fonollosa, J. A. Román, M. Alirangues
MANIFESTATIONS OF SYSTEMIC SCLEROSIS IN PATIENTS WITH DIFFERENT INITIAL RENAL STATUS
V. Semenov, T. Lysunets, O. Kuryata

RISK FACTORS ASSOCIATED WITH DECREASED GLOMERULAR FILTRATION RATE IN SYSTEMIC SCLEROSIS
P. Ostojic, N. Stojanovski, N. Damjanov

ACUTE KIDNEY INJURY IN A SYSTEMIC SCLEROSIS PATIENT
S. Puksic, A. Sutic, J. Morovic-Vergles

SCLERODERMA RÉNAL CRISIS . ABOUT ONE CASE
O. Mkinsi

EXPOSURE TO ACE INHIBITORS PRIOR TO ONSET OF SCLERODERMA RENAL CRISIS IS NOT ASSOCIATED WITH INCREASED RISK OF MORTALITY IN A LARGE RETROSPECTIVE COHORT STUDY
S. R. Johnson, M. Elarabi, S. Proudman, T. Frech, J. Sahhar, W. Stevens, J. Zochling, Z. Ahmad, Canadian Scleroderma Research Group, M. Baron, M. Hudson

DETECTION OF ANTINUCLEAR ANTIBODIES BY INDIRECT IMMUNOFLUORESCENCE AND A COMPARISON OF THEM TO ANTI-SCL-70 AND ANTI-ENA ANTIBODIES DETECTED USING ELISA IN PATIENTS SUFFERING FROM SYSTEMIC SCLERODERM

THE PREVALENCE AND SIGNIFICANCE OF ANTI-PM/SCL ANTIBODIES IN SYSTEMIC SCLEROSIS
E. Wielosz, M. Majdan, M. Dryglewska

PREVALENCE AND PREDICTORS OF HAND INVOLVEMENTS IN THAI PATIENTS WITH SYSTEMIC SCLEROSIS
S. Wangkaew, C. Sivasomboon, W. Leungwattananon, N. Kasitanon, W. Louthrenoo

EXTENSIVE PHYSICAL THERAPY FOR THE TREATMENT OF HAND FUNCTION IMPAIRMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS

CAVEOLIN-1 REVERSED EFFECT OF PROFIBROTIC CYTOKINES ON MONOCYTES TO ADIPOCYTES DIFFERENTIATION

TUMORAL CALCINOSIS IN SYSTEMIC SCLEROSIS: FOUR NEW CASES AND REVIEW OF THE LITERATURE
E. Toniol, J. Avouac, I. Castellvi, J. Nanáez, Y. Allanore

CLINICAL UTILITY OF SALT & PEPPER SKIN IN DIFFUSE SYSTEMIC SCLEROSIS
K. Solanki, C. Hor, W.S.J. Chang, D.H.N. White

PREVALENCE OF OTHER AUTOIMMUNE DISEASES IN PATIENTS WITH SYSTEMIC SCLEROSIS - A SINGLE CENTER STUDY

FOOT PAIN AND LESIONS IN SYSTEMIC SCLEROSIS: IS THERE ANY ASSOCIATION WITH ORGAN INVOLVEMENT?
S. Poormoghim, E. Andalib, A. Jalali, A. Almasi

USE OF ADAPTIVE STRATEGIES BY PERSONS WITH SYSTEMIC SCLEROSIS TO PERFORM DAILY ACTIVITIES
J. Poole, V. Stofer

FEASIBILITY OF SUBMAXIMAL EXERCISE TESTS IN PATIENTS WITH SYSTEMIC SCLEROSIS IN A CLINICAL SETTING
H. Pettersson, H. Alexanderson, E. Svenungsson, A. Nordin, C. Bostrom

LONG-TERM EFFICACY OF SELF-ADMINISTRATED STRETCHING FOR FINGER FUNCTION IN JAPANESE PATIENTS WITH SYSTEMIC SCLEROSIS
N. Mugii, Y. Hamaguchi, S. Oohata, T. Matsushita, K. Takehara

REHABILITATION IN SYSTEMIC SCLEROSIS BY VOCAL INTERVENTION: FROM CASE TO CONCEPT?
M. Mickel, T. Stegemann, R. Crevenna
P.303  THE EFFECT OF PARAFFIN BATH PRIOR TO HAND EXERCISES FOR PATIENTS WITH SYSTEMIC SCLEROSIS  
L. Qvist Kristensen, L. Gregersen Oestergaard, K. Bovbjerg, K. Soendergarrd

P.304  HANDS ON – A HAND CARE GUIDE IN SYSTEMIC SCLEROSIS  

P.305  ANTI-HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN (ANTI- HNRNP) AND OTHER AUTOANTIBODIES IN SYSTEMIC SCLEROSIS WITH JOINT INVOLVEMENT IN COMPARISON BY JOINT X- RAY  
N. Fathi, N. Ismail, S. Goma, A. M. Ghandour, S. Hussein, E. Mosad

P.306  OSTEOPOROSIS IN A HUNGARIAN SCLERODERMA PATIENT’S COHORT  
Á. Honáth, G. Szucs, S. Szamosi

P.307  A NEW OVERLAP SYNDROME: SYSTEMIC LUPUS ERYTHEMATOSUS AND SCLEROMYOSITIS: A CASE REPORT  

P.308  SCLEROMYOSITIS: ABOUT 2 CASES  

P.309  MORPHEA IN A ZOSTERIFORM DISTRIBUTION- A RARE CLINICAL ENTITY  
L. Groseanu, T. Gudu, R. Ionescu

P.310  WAX BATHS DO NOT MAKE HAND EXERCISES MORE EFFECTIVE IN PEOPLE WITH SYSTEMIC SCLEROSIS: A RANDOMISED CONTROLLED TRIAL.  
W. J. Gregory, P. R. Briffa, K. L. Young, J. Wilkinson, A. L. Herrick

P.301  DISSECTING THE ROLE OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT-3) IN SYSTEMIC SCLEROSIS  
G. Febriana, S. O’Reilly, J. M. Van Laar

P.312  PREVALENCE AND PREDICTORS OF DIGITAL ULCERS IN A COHORT OF SYSTEMIC SCLEROSIS  

P.303  EFFECT OF RESPIRATORY MUSCLE TRAINING ON EXERCISE PERFORMANCE IN SYSTEMIC SCLEROSIS. A PILOT STUDY  
M. Buslau, St. Vogt, Th. Ettlin

P.314  SYSTEMIC SCLEROSIS AND OSTEOPOROSIS  
P. Athanassiou, A. Tzanavari, T. Banti, C. Katsavouni, A. Spyridis, I. Kostoglou-Athanassiou

P.315  MAGNETIC RESONANCE IMAGING OF SACROIILIAC JOINTS IN SYSTEMIC SCLEROSIS PATIENTS  
D. Arslan Tas, I. Turk, O. Kudas, B. Kelle, H. Sakalli

P.316  THE RELEVANCE OF MODERN IMAGING FOR THE DIAGNOSIS OF OROFACIAL PATHOLOGY IN SYSTEMIC SCLEROSIS: A CASE REPORT OF MANDIBULAR CONDYLAR RESORPTION  
C. Ancuta, C. Iordache, M. Antohe

P.317  BONE MINERAL DENSITY AND FRACTURE RISK IN AN EUSTAR COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS  
C. Ancuta, C. Belibou, R. Maxim, C. Pomirleanu, R. Chirieac

P.318  SUBCUTANEOUS CALCINOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS  
A. Abdessemed, N. Khaldoun, A. Djoudi, R. Chetouane, S. Haid, N. Brahimi, A. Ladjouze

---

**GASTROINTESTINAL / NUTRITION**

P.319  GASTROINTESTINAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: CASE STUDY OF A RHEUMATOLOGY UNIT  

P.320  PRIMARY BILIARY CIRRHOSIS DURING THE SCLERODERMA SYSTEMIC  
D. Si Ahmed, F. Haddoum, M. Bouali-Benhalima, F. Bouali

P.321  PHARYNGO OESOPHAGEAL DYSPHAGIA IN SCLERODERMA – AN UNDER RECOGNISED, POTENTIALLY FATAL BUT TREATABLE PHENOMENON  
C. Rajapakse

P.322  SOCIAL AND PSYCHOLOGICAL IMPACT OF GASTROINTESTINAL INVOLVEMENT IN SSC – ROMANIAN SURVEY  
A. Petcu, I.R Dobrota, S. Rednic
REYNOLDS SYNDROME – THE COEXISTENCE OF TWO RARE AUTOIMMUNE DISEASES
P. Monteiro, R. Fernandes, M. Moreira, C. Silva, P. Ferreira, C. Coelho, A. Seixas, V. Paixão Dias

FECAL INCONTINENCE AND ASSOCIATION WITH BOWEL DYSFUNCTION IN SYSTEMIC SCLEROSIS: A CANADIAN MULTICENTER STUDY

FRUCTOSE MALABSORPTION IN SYSTEMIC SCLEROSIS
I. Marie

EOSINOPHILIC FASCIITIS AS A PARANEoplastIC MANIFESTATION: CASE REPORT AND REVIEW OF THE LITERATURE
C. Manzini, G. Cassone, C. Vacchi, M. Colaci, M. Sebastiani, E. Cocchiara, C. Ferri

ABNORMAL VITAMIN-D LEVELS AND GASTROINTESTINAL (GI) MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC)
A. Aly, Y. Suliman, Y. Shaweesh, M. Alemam, I. Valera, S. Vangala, D. Elahoff, P. Clements, D. Furst, S. Kafaja

IMPACT OF PROKINETIC AGENTS ON SYSTEMIC SCLEROSIS-ASSOCIATED GASTROINTESTINAL DISEASE: A SYSTEMATIC REVIEW
A. Tisseverasinghe, A. Kadhim, A. Parmar, L. Liu, S. Johnson

SEVERITY OF GASTROINTESTINAL SYMPTOMS IN THE PROSPECTIVE REGISTRY OF EARLY SYSTEMIC SCLEROSIS (PRESS) COHORT.

ASSESSMENT OF SUBLINGUAL FRENULUM PERFUSION IN SYSTEMIC SCLEROSIS

EFFECTIVENESS OF ADD-ON THERAPY WITH DOMPERIDONE VS. ALGINIC ACID IN PROTON PUMP INHIBITOR PARTIAL RESPONSE GASTROESOPHAGEAL REFUX DISEASE IN SYSTEMIC SCLEROSIS: RANDOMIZED PLACEBO CONTROLLED TRIAL
C. Foucharoen, K. Chunlerthith, P. Mairiang, A. Mahakkanukrauh, S. Suwannaroj, S. Namvijit, O. Wantha, R. Nanagara

NUTRITIONAL ASSESSMENT IN A COHORT OF PATIENTS WITH SCLERODERMA
M. Cusa, M.F. Cusa, S. Scarafia, M.A Lazaro

ETIOLOGICAL PROFILE OF DIGESTIVE AFFECTION IN DIFFUSE SYSTEMIC SCLEROSIS AND CREST SYNDROME: STUDY OF 32 PATIENTS.
G. Chalhoub, G. Brabant, M.L. Scherrer, B. Benet, P. Okamba, M. Valla

GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS PATIENTS: LONG-TERM PROGNOSIS AND TREATMENT
Y. Braun-Moscovici, M. Braun, I. Hermesh, Y. Tavor, M. Nafaa, R. Beshara-Garzoz, D. Markovits, K. Toledano, A. Rozin, A. Balbir Gurman

PERSISTENT REFUX ESOPHAGITIS EVALUATED BY ESOPHAGOGASTRODUODENOSCOPY IN THE PATIENTS WITH SYSTEMIC SCLEROSIS
H. Baek, H. Ryu, M. Seo, H. Choi

GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS: A COMMON AND SERIOUS FEATURE OF THE DISEASE

ESOPHAGEAL DILATION AND HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC SCLEROSIS
M. Blanco, M. Ma, J. Lee, R. Agrawal, R. W. Chang, M. Hinchcliff
P.338 SYSTEMIC SCLEROSIS IN A COHORT OF MEN
D. Si Ahmed, H. Haddoum, M. Bouali-Benhalima, F. Bouali

P.339 EXPOSURE TO BOSENTAN IN EARLY PREGNANCY: A CASE REPORT
V. Ramoni, M. Betelli, G. Grosso, S. Rampello, M.L. Farina, G. Contessa, G. Bacis, M. Limonta, A. Brucato

P.340 JUVENIL LOCALIZED SCLERODERMA OR LICHEN SCLEROSIS OF ANOGENITAL AREA?
M. Osminina, N. Geppe, V. Volnukhin, J. Kostina, O. Shpitonkova

P.341 PREGNANCY IMPROVES MICROCIRCULATION IN SSC PATIENTS. CAPILLAROSCOPIC STUDY
C. Pintaudi, R. Cimino, S. Mazzuca

P.342 FERTILITY AND PREGNANCY IN SYSTEMIC SCLEROSIS – A EUSTAR CENTER EXPERIENCE

P.343 CLINIC AND MORTALITY DIFFERENCES BETWEEN SCLERODERMIC MEN AND WOMEN OF THE RESCLE COHORT

P.344 RATES AND CORRELATES OF SEXUAL DYSFUNCTION IN SYSTEMIC SCLEROSIS AND LUPUS PATIENTS: A CASE-CONTROLLED STUDY

P.345 WITHDRAWN

P.346 LONGITUDINAL ANALYSIS OF MMF CLINICAL AND MOLECULAR RESPONSES SHOW SSC PATIENTS LOSE THEIR INFLAMMATORY SIGNATURE AND REBOUND UPON TREATMENT CESSATION

P.347 EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: EXPERIENCES IN A ROUTINE CLINICAL SETTING
Y. Shirai, T. Takeuchi, M. Kuwana

P.348 USE OF RITUXIMAB PLUS CYCLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS LUNG FIBROSIS
M. Saracco, R. Vitetta, G. Rovera, R. Pellerito

P.349 RITUXIMAB IN TREATMENT OF SYSTEMIC SCLEROSIS PATIENTS WITH REFRACTORY MYOPATHY – CASE SERIES
M. Radic, D. Martinovic Kaliterna, D. Perkovic, D. Marasovic Krstulovic, K. Boric

P.350 THE EFFICACY OF FOSTAMATINIB THERAPY ON ISCHEMIA-REPERFUSION INJURY IN A BLEOMYCIN-INDUCED SCLERODERMA MOUSE MODEL
O. Pamuk, G. Can, T. Karaca, S. Ayvaz, S. Demirtas, G. Pamuk, G. Tsokos

P.351 SUCCESSFUL IMPROVEMENT OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS PATIENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: CASE REPORT
TOCILIZUMAB IN A CASE OF SSC WITH AN UNYIELDING PROGRESSION TO SEVERE FIBROSIS
J. Oliveira, A. Brasileiro, C. Costa, R. Ribeiro, M. Marques Silva, S. Pinheiro, A. Castro

SINGLE SAMPLE PREDICTOR (SSP) FOR MOLECULAR CLASSIFICATION OF SKIN BIOPSIES OF PATIENTS WITH SYSTEMIC SCLEROSIS - UTILIZING GENE EXPRESSION PROFILING TO GUIDE PATIENT MANAGEMENT

THERAPEUTIC EFFECT OF MESENCHYMAL STEM CELLS IN A MURINE MODEL OF SYSTEMIC SCLEROSIS

PRELIMINARY DATA ON USE OF TOCILIZUMAB IN REFRACTORY JUVENILE LOCALISED SCLERODERMA
H. Lythgoe, E. Baildam, M.W. Beresford, G. Cleary, L.J. McCann, E. Pain

A COMPARATIVE REVIEW OF THE NEW EULAR/EUSTAR AND BRITISH SYSTEMIC SCLEROSIS EVIDENCE BASED TREATMENT RECOMMENDATIONS
J. Lee, R. Pellar, J. Pope

A CASE REPORT OF A LOCALIZED SCLERODERMA IMPROVED BY COLCHICINE

PRELIMINARY SAFETY AND EFFICACY DATA FROM THE ONGOING FASSCINATE TRIAL OF SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS

NARROW BAND – 365 NM ULTRAVIOLET A1 LIGHT THERAPY IN BLEOMYCIN-INDUCED SCLERODERMA ANIMAL MODEL
D. Karpec, R. Rudys, Z. Mackiewicz, L. Leonaviciene, R. Bradunaite, R. Rugiene, G. Kirdaite, A. Venalis

ANTI-FIBROTIC POTENTIAL OF CPA ON DERMAL FIBROBLASTS IN SYSTEMIC SCLEROSIS
T. Higuchi, Y. Kawaguchi, K. Takagi, A. Tochimoto, Y. Ichimura, H. Yamanaka, K. Okada

ANALYSIS OF HUMORAL IMMUNE RECONSTITUTION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: MOLECULAR RECOGNITION PATTERNS OF ANTI-TOPO-ISOMERASE I ANTIBODIES
J. Henes, L. Glaesser, L. Kanz, W. Vogel, R. Klein

Efficacy of autoologous microfat graft on facial handicap in systemic sclerosis patients

DEVELOPMENT OF TOPICAL FORMULATIONS FOR TRANSDERMAL DELIVERY OF VASODILATORS IN RAYNAUD’S PHENOMENON
A. Gallas, M. Wareing, L.K. Harris, A. Herrick, A.Ch. Hunter

VASODILATING AND VASOACTIVE TREATMENT IN CLINICAL CARE OF SYSTEMIC SCLEROSIS: A REPORT FROM THE DESSCIPHER PROJECT OF THE EUSTAR GROUP

WITHDRAWN

CURRENT IMMUNOSUPPRESSIVE TREATMENT PATTERNS IN ROUTINE CLINICAL CARE OF SYSTEMIC SCLEROSIS: A REPORT FROM THE DESSCIPHER PROJECT OF THE EUSTAR GROUP

COMBINATION THERAPY WITH RITUXIMAB AND MYCOPHENOLATE MOFETIL IN SYSTEMIC SCLEROSIS. PRELIMINARY ANALYSIS OF A COHORT OF PATIENTS
P. Fraticelli, C. Fischetti, L. Manfredi, M. Mattioli, A. Gabrielli

TOCILIZUMAB – A NOVEL PROMISING THERAPY IN SYSTEMIC SCLEROSIS
A. Duarte, I. Cordeiro, A. Cordeiro, M.J. Santos
POSTER SESSION

P.371  INTERLEUKIN 6 INHIBITOR TOCILIZUMAB LIMITS TISSUE DAMAGE AND FIBROSIS IN A BLEOMYCIN-INDUCED SCLERODERMA MOUSE MODEL
S. Donmez, Y. Bozdemir Donmez, M. Erboga, G. Can, M. Kanter, G.E. Pamuk, O.N. Pamuk

P.372  TYROSINE KINASE INHIBITORS DASATINIB LIMITS TISSUE DAMAGE AND FIBROSIS IN A BLEOMYCIN-INDUCED SCLERODERMA MOUSE MODEL
Y. Bozdemir Donmez, M. Erboga, S. Donmez, G. Can, G. E. Pamuk, M. Kanter, O. N. Pamuk

P.373  RIOICIGUAT IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: RISE-SSC STUDY DESIGN AND RATIONALE
O. Distler, J. Pope, C. Denton, Y. Allanore, M. Matucci-Cerinic, J. de Oliveira Pena, D. Khanna

P.374  RITUXIMAB IN SYSTEMIC SCLEROSIS: RESULTS OF A RANDOMIZED PLACEBO CONTROLLED TRIAL

P.375  CXCL10 CHANGES DURING THERAPIES IN SYSTEMIC SCLEROSIS. AN IN VIVO AND IN VITRO STUDY
C. Corinaldesi, C. Antinozzi, G. Valesini, K. Stefanantoni, I. Sciarrà, V. Riccieri, L. Di Luigi, A. Lenzi, C. Crescioli

P.376  RITUXIMAB IN THE TREATMENT OF SYSTEMIC SCLEROSIS: THE EXPERIENCE OF OUR TERTIARY REFERRAL RHEUMATOLOGY CENTRE
D. Giuggioli, M. Colaci, F. Lumetti, C. Ferri

P.377  THE SAFETY OF RITUXIMAB THERAPY IN SYSTEMIC SCLEROSIS: A SINGLE CENTRE EXPERIENCE
L. Ananyeva, O. Koneva, O. Desinova, O. Ovsyannikova, A. Volkov, L. Gorzanova, M. Starovoytova

NEW REGISTRY

P.378  ROLE OF NAILFOLD VIDEOCAPILLAROSCOPY IN DIAGNOSIS AND EVALUATION OF CHINESE SYSTEMIC SCLEROSIS PATIENTS

P.379  A PROSPECTIVE STUDY TO IDENTIFY RISK FACTORS FOR PROGRESSIVE CALCINOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: CURRENT STATUS AND PRELIMINARY DATA

P.380  NAILFOLD CAPILLAROSCOPY IN CONNECTIVE TISSUE DISEASES - A SINGLE CENTER EXPERIENCE
L. Teixeira, I. Cordeiro, J. Canas da Silva, M. José Santos, A. Cordeiro

P.381  AUTOIMMUNE/INFLAMMATORY SYNDROME INDUCED BY ADJUVANTS – A CASE REPORT ABOUT SILICON-INDUCED SYSTEMIC SCLEROSIS
P. Silva, R. Malheiro, S. Pinheiro

P.382  OCULAR INVOLVEMENT AND GENITAL MUCOSA LESIONS IN A MALE TEENAGER WITH SYSTEMIC SCLEROSIS – A RARE ASSOCIATION
M. Salgado, L. Theilacker, J. Vaz, F. Freire, S. Francisco, F. Bandeira, D. Sugui

P.383  CANCER INCIDENCE IN PATIENTS WITH SYSTEMIC SCLEROSIS IN THE STATE OF RIO DE JANEIRO – BRAZIL
M. Salgado, S. Merenlender, J. Vaz, F. Freire, D. Sugui, L. Theilacker

P.384  SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE: 2013 AMERICAN COLLEGE RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM CLASSIFICATION CRITERIA VERSUS 1980 ARA/ACR CLASSIFICATION CRITERIA
P.385 CONCORDANCE OF NEW 2013 ACR/EULAR AND 1980 ACR CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC SCLEROSIS

P.386 INCIDENCE, PREVALENCE AND FIVE-YEAR SURVIVAL OF SYSTEMIC SCLEROSIS (SSC) IN SPLIT-DALMATIA COUNTY
M. Radic, M. Cikes, I. Bozic, J. Borovac, K. Boric, D. Martinovic Kaliterna

P.387 IRANIAN SYSTEMIC SCLEROSIS REGISTRY
S. Poormoghim, R. Talebi, M. Amiri, E. Andalib

P.388 SCLERODERMA RENAL CRISIS AND SEVERE VASCULOPATHY IN ANA NEGATIVE SSC PATIENT- A CASE REPORT
A. Petcu, R. Nichitean, I. R. Dobrota, S. Rednic

P.389 USEFULNESS OF THE EUSTAR PRELIMINARY CRITERIA FOR VERY EARLY SYSTEMIC SCLEROSIS AND LE ROY CRITERIA FOR EARLY-SYSTEMIC SCLEROSIS IN IDENTIFYING PATIENTS AT RISK OF DEVELOPMENT OF SYSTEMIC SCLEROSIS

P.390 AUTOANTIBODY AND CLINICAL PROFILE OF SSC PATIENTS IN A SINGLE CENTER – RETROSPECTIVE ANALYSIS
J. Milas-Ahic, V. Prus, Z. Kardum, I. Kovacevic

P.391 MYOPATHY ASSOCIATED WITH SSC – A JOINT EUSTAR-SCTC SUB-COHORT INITIATIVE
B. Maurer, R. Dobrota, V. Jaeger, L. Chung, V. Hsu, U.A. Walker, O. Distler

P.392 REGISTRIES IN SCLERODERMA, DATA FROM THE PORTUGUESE NATIONAL REGISTRY R.I.D.A.I.– PART I

P.393 SYSTEMIC SCLEROSIS OVERLAP SYNDROMES: A PARTICULAR SUBSET OF SYSTEMIC SCLEROSIS PATIENTS
T. Martins Rocha, R. Fonseca, F. Aguiar, D. Rosa-Gonçalves, T. Meirinhos, A. Bernardo, M. Bernardes, L. Costa

P.394 SYSTEMIC SCLEROSIS – POPULATION OF AN INTERNAL MEDICINE DEPARTMENT

P.395 PANICULITIS ASSOCIATED WITH A NEURO BEHCET : A CASE REPORT

P.396 INFLUENCE OF ANTIBODY PROFILE IN CLINICAL FEATURES AND PROGNOSIS IN A SPANISH COHORT OF SYSTEMIC SCLEROSIS
N. Iniesta, G. Espinosa, V. Fonollosa, D. Colunga, N. Ortego, M. Rubio, J.A. Vargas, L. Trapiella, M. Rodríguez-Carballeira, C.P. Simeón

P.397 SENSITIVITY AND SPECIFICITY OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN JAPANESE PATIENTS WITH EARLY SYSTEMIC SCLEROSIS
Y. Ikawa, N. Mugii, T. Matsushita, Y. Hamaguchi, K. Takehara

P.398 SCLERODERMA CLINICAL TRIALS CONSORTIUM GASTROINTESTINAL WORKING GROUP
T. Frech, Z. McMahan, G. Piemonte, M. Matucci-Cerinic, S. Proudman, D. Khanna

P.399 PERFORMANCE OF THE EULAR/ACR 2013 CLASSIFICATION CRITERIA IN A PORTUGUESE SYSTEMIC SCLEROSIS POPULATION
A. Fonseca, D. Rosa-Gonçalves, F. Aguiar, T. Martins-Rocha, T. Meirinhos, E. Mariz, M. Bernardes, L. Costa

P.400 THE RARE DISEASES COLLECTOR
C. Costa, J. Oliveira, S. Pinheiro

P.401 REUMA.PT/SCL – THE PORTUGUESE REGISTRY FOR SCLERODERMA PATIENTS
A. Cordeiro, C. Ponte, M. Couto, I. Cordeiro, M.J. Salvador, F. Araújo, P. Clemente-Coelho, M. Eusébio, F. Martins, M.J. Santos

P.402 CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS IN QATAR
S. Al-Emadi, F. Alam, I. Ul Haq, P. Chandra, H. Abdulaziz
Congress Venue
Lisbon Congress Center
Praça das Indústrias
1300-307 Lisboa, Portugal

How to get to the congress venue
Travel from Cais do Sodré (following bus and tram) to the Lisbon Congress Centre (station name: R. Junqueira/Centro de Congressos):
Bus 732: Marquês Pombal/Outurela
Tram 15E: Algés/Praça da Figueira

Following buses are also available from the station R. Junqueira/Centro Congressos:
Bus 714: Praça da Figueira / Outurela
Bus 727: Estação Roma-Areeiro / Restelo – Av. Descobertas
Bus 751: Estação Campolide / Linda-a-Velha
Bus 756: Olaias / R. Junqueira

Subway
Take the blue Line from the Marques de Pombal metro station to Terreiro do Paço metro station and there catch the tram n° 15. Or take the blue Line until Cais do Sodre and there catch the tram n° 15. Stop at the R. Junqueira/Centro de Congressos

Organizing Secretariat
AIM Group International
AIM Congress – Florence Office
Viale G. Mazzini, 70 – 50132 Florence, Italy
Tel. +39 055 233881 – Fax +39 055 2480246
ssc2016@aimgroup.eu

Onsite the registration desk will be open for participants at the following times: Thursday, February 18 from 11:30 to 20:00, Friday, February 19 from 07:30 to 18:30 and Saturday, February 20 from 07:30 to 17:00

REGISTRATION FEES (VAT incl.)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>€ 830,00</td>
</tr>
<tr>
<td>Young Investigators*/ Fellows</td>
<td>€ 365,00</td>
</tr>
<tr>
<td>PhD Basic Scientists</td>
<td>€ 365,00</td>
</tr>
<tr>
<td>HP (Nurses and Physiotherapists)</td>
<td>€ 365,00</td>
</tr>
<tr>
<td>Medical Students**</td>
<td>€ 240,00</td>
</tr>
<tr>
<td>Patients</td>
<td>€ 35,00</td>
</tr>
</tbody>
</table>

* For young doctors under 30 years of age. Copy of the ID or passport is requested.
** These individuals must include a letter from their program director, chief of service or faculty advisor to be eligible for reduced fees.
Registration fees include:
Congress kit, access to the scientific sessions, admission to the exhibition and poster area, certificate of attendance, coffee breaks and working lunches as indicated in the programme and abstracts book, online subscription for one year to “Journal of Scleroderma and Related Disorders”.

Registration fee for patients includes:
Congress kit, access to the Opening Ceremony of the medical congress, scientific sessions of the patient congress only, coffee breaks and working lunch as indicated in the patient programme.

Congress badges
Each participant may collect the badge at the registration desk. Participants are kindly requested to wear their badge during all congress activities and social events.

No colour: Participants
Red colour: Invited Speakers and Chairpersons
Yellow colour: Exhibitors
Blue colour: Patients

Internet connection
Free wi-fi connection is available in all congress spaces except in the poster area.
Wifi: SSC2016
Password: SSC2016

Language
The official language is English.

Catering
Coffee breaks
Coffee breaks will be organized in the exhibition area, first floor, Hall 4, during the following times:
Friday, February 19
from 10:40 to 11:00 and from 16:55 to 17:15
Saturday, February 20
from 10:20 to 10:40

Lunches
A standing buffet lunch will be offered to all registered participants on Friday, February 19 from 13:45 to 14:45 and on Saturday, February 20 from 12:40 to 13:30 in exhibition area, first floor, hall 4.

Certificate of Attendance
Certificates of attendance will be available on request starting from Saturday, February 20 at the Registration desk.

Exhibition
An exhibition will be open in the following days at Hall 4 at the first floor: Thursday, February 18 from 15:00 to 19:30, Friday, February 19 from 08:00 to 19:00, Saturday, February 20 from 08:00 to 13:30.

Social Programme
Welcome Cocktail – Thursday, February 18
A welcome cocktail will be held after the Opening Ceremony in the foyer at the first floor for all registered participants.

Congress Dinner – Friday, February 19
The seated Congress Dinner with buffet service will be held at “Pateo Alfacinha”, Rua do Guarda Joias, 44. Informal evening with typical Portuguese menu. Transfer by bus, upon reservation, will be provided from the Congress Center at 19:30. For those who want to reach Pateo Alfacinha on their own the evening will start at 19:50. Remaining tickets will be sold to the “New registration” desk until Friday, February 19 at 10:00.
<table>
<thead>
<tr>
<th>Space nr.</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Therakos</td>
</tr>
<tr>
<td>02</td>
<td>Optilia Instruments</td>
</tr>
<tr>
<td>03</td>
<td>Cytori Therapeutics</td>
</tr>
<tr>
<td>04</td>
<td>DS Medica</td>
</tr>
<tr>
<td>05</td>
<td>World Scleroderma Foundation, EUSTAR Journal of Scleroderma &amp; Related Diseases</td>
</tr>
<tr>
<td>08, 09, 10, 11</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>12, 13, 14, 15</td>
<td>Bayer</td>
</tr>
<tr>
<td>16</td>
<td>Actelion</td>
</tr>
</tbody>
</table>
Abstract sessions
Selected papers will be orally presented by the Authors. Authors have the time indicated in the programme including the discussion.

Poster Session
Poster session will take place in the Poster Area at the first floor on *Friday, February 19* from 13:45 to 14:45 and on *Saturday, February 20* from 12:40 to 13:30. Authors have been given a number and must be fixed on the poster board marked with the same number. Posters can be hanged from 15:00 to 18:00 of *Thursday, February 18* and from 07:45 of *Friday, February 19* and removed within 17:00 of *Saturday, February 20*.

Poster panel height is cm 215 and the usable surface in vertical size is cm. 90 (wide) and cm. 135 (height).

Authors are kindly asked on Friday 19 and Saturday 20 to stand by their poster during the Poster Session time for discussion with delegates. Otherwise please hang a note to inform when you will be available.

Meet the Professors session
Meet the Professors sessions will be organized on *Saturday, February 20* from 08:00 to 09:00 (see the scientific program) for young practicing physicians only, for a maximum of 20 participants each, on first come, first served basis. Remaining places can be booked at the “New registration” desk.

Slide Center
The Slide Center is available in the room 1.14 at the first floor. Speakers are kindly requested to load their slides in the Slide Center at least three hours before their presentation (or, if their session starts at 8:00, by 18:00 on the previous day).
The opening hours of the slide center are: *Thursday, February 18*, from 11:30 to 19:00, *Friday, February 19* from 07:30 to 18:30 and *Saturday, February 20*, from 07:30 to 16:00.

Abstract book
The abstracts of the oral presentations and posters are included in the *Journal of Scleroderma and Related Disorders* in the congress bag.
The Congress Organisers gratefully acknowledge support received from all exhibitors and the following sponsors:

**Platinum Sponsor:**

![Actelion](image)

**Gold Sponsors:**

![Bayer](image) ![gsk](image) ![Boehringer Ingelheim](image)

**Silver Sponsor:**

![Therakos](image)